Nanobiotix (NBTX) 6-K 8 Sep 21 2021 Q2 Current report (foreign) Financial data

Cover page

Cover page	6 Months Ended
	Jun. 30, 2021
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	NANOBIOTIX S.A.
Entity Address, Address Line One	60 rue de Wattignies
Entity Address, Postal Zip Code	75012
Entity Address, City or Town	Paris
Entity Address, Country	FR
Amendment Flag	false
Entity Central Index Key	0001760854
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

INTERIM CONDENSED STATEMENTS OF

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	€ 12	€ 21
Property, plant and equipment	7,535	8,256
Non-current financial assets	498	505
Total non-current assets	8,045	8,782
Current assets
Trade receivables	0	62
Other current assets	13,534	6,035
Cash and cash equivalents	102,336	119,151
Total current assets	115,870	125,248
TOTAL ASSETS	123,915	134,030
Shareholders’ equity
Share capital	1,045	1,033
Premiums related to share capital	255,782	255,735
Accumulated other comprehensive income	513	555
Treasury shares	(212)	(196)
Reserve	(185,276)	(153,069)
Net loss for the period	(30,420)	(33,590)
Total shareholders’ equity	41,431	70,468
Non-current liabilities
Non-current provisions	457	414
Non-current financial liabilities	43,988	44,107
Total non-current liabilities	44,445	44,522
Current liabilities
Current provisions	430	40
Current financial liabilities	6,730	4,872
Trade payables and other payables	8,813	7,106
Other current liabilities	5,510	7,022
Deferred revenues and contract liabilities	16,555	0
Total current liabilities	38,038	19,041
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	€ 123,915	€ 134,030

INTERIM CONDENSED STATEMENTS _2

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED OPERATIONS - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenues and other income
Revenues	€ 10	€ 37
Other income	1,309	1,411
Total revenues and other income	1,319	1,448
Research and development expenses	(15,506)	(13,077)
Selling, general and administrative expenses	(10,176)	(6,755)
Other operating income and expenses	(5,414)	0
Total operating expenses	(31,096)	(19,832)
Operating income (loss)	(29,778)	(18,384)
Financial income	2,511	234
Financial expenses	(3,152)	(2,428)
Financial income (loss)	(640)	(2,194)
Income tax	(2)	(1)
Net loss for the period	€ (30,420)	€ (20,579)
Basic loss per share (in euro per share)	€ (0.88)	€ (0.91)
Diluted loss per share (in euro per share)	€ (0.88)	€ (0.91)

INTERIM CONDENSED STATEMENTS _3

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement of comprehensive income [abstract]
Net loss for the period	€ (30,420)	€ (20,579)
Tax impact	0	0
Other comprehensive loss that will not be reclassified subsequently to income or loss	0	0
Currency translation adjustment	(42)	(5)
Tax impact	0	0
Other comprehensive income that may be reclassified subsequently to income or loss	(42)	(5)
Total comprehensive loss	€ (30,462)	€ (20,584)

INTERIM CONDENSED STATEMENT OF

INTERIM CONDENSED STATEMENT OF CONSOLIDATED CHANGES IN SHAREHOLDERS’ EQUITY - EUR (€) € in Thousands	Total	Share capital Ordinary shares	Premiums related to share capital	Accumulated other comprehensive income (loss)	Treasury shares	Reserve	Net loss for the period
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2019		22,415,039
Equity at beginning of period at Dec. 31, 2019	€ (1,909)	€ 672	€ 153,139	€ 433	€ (169)	€ (105,070)	€ (50,915)
Net loss for the period	(20,579)						(20,579)
Currency translation adjustments	(5)			(5)
Total comprehensive loss	(20,584)			(5)			(20,579)
Allocation of prior period loss	0					(50,915)	50,915
Capital increase (in shares)		316,083
Capital increase, net	0	€ 9				(9)
Subscription of warrants	5		5
Share-based payment	1,542					1,542
Treasury shares	(74)				(74)
U.S. Initial public offering costs offset	(1,175)		(1,175)
Number of shares outstanding at end of period (in shares) at Jun. 30, 2020		22,731,122
Equity at end of period at Jun. 30, 2020	(22,194)	€ 682	151,968	428	(243)	(154,451)	(20,579)
Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2020		34,432,122
Equity at beginning of period at Dec. 31, 2020	70,468	€ 1,033	255,735	555	(196)	(153,069)	(33,590)
Net loss for the period	(30,420)						(30,420)
Currency translation adjustments	(42)			(42)
Total comprehensive loss	(30,462)			(42)			(30,420)
Allocation of prior period loss	0					(33,590)	33,590
Capital increase (in shares)		393,750
Capital increase, net	0	€ 12	(12)
Subscription of warrants	43		43
Share-based payment	1,398					1,398
Treasury shares	(16)				€ (16)
Other movements	0		16			(16)
Number of shares outstanding at end of period (in shares) at Jun. 30, 2021		34,825,872			15,053
Equity at end of period at Jun. 30, 2021	€ 41,431	€ 1,045	€ 255,782	€ 513	€ (212)	€ (185,276)	€ (30,420)

INTERIM CONDENSED STATEMENTS _4

INTERIM CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows used in operating activities
Net loss for the period	€ (30,420)	€ (20,579)
Elimination of other non-cash, non-operating income and expenses
Depreciation and amortization	801	906
Provisions	432	(126)
Expenses related to share-based payments	1,398	1,542
Cost of net debt	1,066	1,046
Impact of deferred income related to financial liabilities discounting effect	2,046	1,343
Other charges with no impact on cash	4	3
Cash flows used in operations, before tax and changes in working capital	(24,673)	(15,864)
(Increase) / Decrease in trade receivables	62	(39)
(Increase) / Decrease in Research tax credit receivable	0	3,314
(Increase) / Decrease in other receivables	(7,504)	(918)
Increase (Decrease) in trade and other payables	2,053	192
Increase / (Decrease) in other current liabilities	(1,442)	435
Increase in deferred income and contract liabilities	16,434	0
Changes in operating working capital	9,602	2,985
Net cash flows used in operating activities	(15,071)	(12,879)
Cash flows from (used in) investing activities
Acquisitions of intangible assets	(4)	(17)
Acquisitions of property, plant and equipment	(45)	(57)
Addition in non-current financial assets	0	(9)
Net cash flows from (used in) investing activities	(50)	(83)
Cash flows from financing activities
Warrants subscription	43	5
Transaction costs	(349)	(261)
Increase in loans and conditional advances	0	5,350
Loans repayments	(250)	0
Payment of lease liabilities	(644)	(171)
Interest paid	(350)	(350)
Charges of lease debt interest	(152)	(169)
Net cash flows from financing activities	(1,703)	4,404
Effect of exchange rates changes on cash	8	54
Net increase (decrease) in cash and cash equivalents	(16,814)	(8,505)
Net cash and cash equivalents at beginning of period	119,151	35,094
Net cash and cash equivalents at end of period	€ 102,336	€ 26,590

Company information

Company information	6 Months Ended
	Jun. 30, 2021
Disclosure Of Information Related To The Company [Abstract]
Company information	Company information Overview of the Company Nanobiotix S.A. (“ Nanobiotix ” or the “ Company ” and, with its subsidiaries, the “ Group ”) is a French biotechnology company in advanced clinical development, pioneering physics-based approaches to expand treatment possibilities for patients with cancer. The Company's philosophy is rooted in one concept: pushing the boundaries of what is known to expand the possibilities of human life. Incorporated in 2003, Nanobiotix is headquartered in Paris (France). The Company also has subsidiaries in the United States (Cambridge, Massachusetts), France, Spain and Germany. Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York since December 2020. Nanobiotix owns more than 30 patent families associated with three nanotechnology platforms for applications in (i) oncology, (ii) bioavailability and (iii) biodistribution and disorders of the central nervous system. The Company's resources are primarily devoted to the development of its main product candidate, NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®. Key events of the six month period ended June 30, 2021 Nanobiotix and PharmaEngine mutually agree to terminate their collaboration In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the “ Termination Agreement ”). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate as described below. PharmaEngine was eligible for and received a $2.5 million payment following the announcement of Nanobiotix’s collaboration with LianBio for the Asia-Pacific region. During the six months ended June 30, 2021, PharmaEngine also received $4.0 million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. PharmaEngine will be eligible to receive an additional $1.0 million in administrative fees and a final payment of an additional $5.0 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of June 30, 2021, these future payments were not accrued because the triggering events have not occurred. As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated. Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates. Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix’s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations. Under the terms of the agreement, the Company received a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies. Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (“the “ Supervisory Board ”). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership. Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the “ Executive Board ”). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.

General information, statement

General information, statement of compliance and basis of presentation	6 Months Ended
	Jun. 30, 2021
General Information, Statement of Compliance and Basis of Presentation [Abstract]
General information, statement of compliance and basis of presentation	General information, statement of compliance and basis of presentation General principles The interim condensed consolidated financial statements as of June 30, 2021 and for the six month period ended June 30, 2021 were prepared under the supervision of the management of the Company and were approved by the Executive Board and reviewed by the Supervisory Board on September 8, 2021. All amounts in the interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. See Note 3.2 Use of judgement, estimates and assumptions. The summarized interim consolidated financial statements of the Company have been prepared in compliance with IAS 34 – “Interim Financial Reporting”. As they are interim condensed financial statements, they do not contain all information required for the consolidated annual financial statements and should therefore be read in conjunction with the consolidated financial statements of the Company for the financial year ended December 31, 2020 as described below. The interim condensed consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning multiple years. With cash and cash equivalents of €102.3 million as of June 30, 2021, the Company believes it has sufficient resources to continue operating for at least twelve months following the interim condensed consolidated financial statements’ publication. Seasonality of the Company’s activities According to IAS 34 – Interim Financial Reporting, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed financial statements in order to provide a better understanding and comparison of its interim financial statements. As mentioned in Note 15 Revenues and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. Therefore, the following interim condensed financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34-20. Statement of compliance and basis of presentation The interim condensed consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of June 30, 2021. The interim condensed consolidated financial statements are also compliant with IFRS as adopted by the European Union. The accounting principles used to prepare the interim condensed consolidated financial statements for the six month period ended June 30, 2021 are identical to those used for the year ended December 31, 2020 except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations whose application was mandatory for periods beginning on or after January 1, 2021: Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2 Flexibility measures relating to the accounting consequences of amendments to contracts following the reform of reference rates and hedge accounting criteria Amendment to IFRS 16 Amendments for COVID-19 related to rent concessions The application of these standards and these amendments had no impact on the interim consolidated condensed financial statements of the Company. Early application of New or Amended Standards and Interpretations The Company elected not to early adopt the new standards, amendments and interpretations, which application was not yet mandatory for the six month period ended June 30, 2021. IFRS 17 Insurance contracts and related amendments Amendment to IAS 1 Classification of liabilities as current and non-current Disclosure of significant accounting policies Update of Practice Statement 2 "Making materiality” Amendment to IAS 37 Onerous Contracts - Cost of Performing a Contract Amendment to IFRS 3 Conceptual Framework Amendment to IAS 8 Definition of an accounting estimate Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use The expected impact of these standards on the consolidated financial statements is not significant.

Consolidated principles and met

Consolidated principles and methods	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
Consolidated principles and methods	Consolidated principles and methods 3.1 BASIS OF CONSOLIDATION Consolidated entities As of June 30, 2021, the consolidation perimeter is identical to that of December 31, 2020 as Nanobiotix S.A. has five wholly owned subsidiaries: • Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA, • Nanobiotix Germany GmbH, created in October 2017 and located in Germany, • Nanobiotix Spain S.L.U., created in December 2017 and located in Spain, • Curadigm SAS, created on July 3, 2019 and located in France, and • Curadigm Corp., created on January 7, 2020 and located in the USA. Accordingly, the interim condensed consolidated financial statements as of June 30, 2021 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation. Foreign currency transactions The unaudited condensed consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar-to-euro exchange rate used in the interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were $1.1884 as of June 30, 2021 and an average of $1.2053 for the six month period ended June 30, 2021 (source: Banque de France) compared with $1.1198 and $1.1015 as of and for the six month period ended June 30, 2020, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment. 3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS The preparation of interim condensed consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., vesting terms) and market data (e.g., expected share volatility) (See Note 17 Share-based payments). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position. Clinical trials accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision is recognized accordingly. (See Note 13.1 Trade and other payables for information regarding the clinical trial accruals as of June 30, 2021 and December 31, 2020). Revenue recognition In order to determine the amount and timing of revenue under the contracts with PharmaEngine and LianBio, the Company is required to use significant judgments, mainly with respect to determining the timing of satisfaction of services provided to PharmaEngine and LianBio (see Note 15 Revenues and other income below for additional detail regarding the revenue recognition related to the new agreement with LianBio). Fair value of financial instruments The fair value measurement of the loan granted by European Investment Bank (‘‘EIB’’) requires the Company to assess the amount of additional interest (‘‘royalties’’, as defined by the royalty agreement with EIB) that will be due according to the loan agreement. The royalties will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s consolidated annual sales turnover generated during a period of six years (“the royalty period”) commencing on January 1, 2021. For purposes of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market.

Significant transactions

Significant transactions	6 Months Ended
	Jun. 30, 2021
Disclosure of transactions between related parties [abstract]
Significant transactions	Significant transactions During the first half of 2021, the Company entered into a new partnership with LianBio (see Note 4.2. LianBio below). The other ongoing significant contracts as of June 30, 2021 are the same ones disclosed in the Consolidated Financial Statements as of December 31, 2020 of the Company and are disclosed again below. 4.1 PHARMAENGINE In August 2012, the Company entered into a license and collaboration agreement with PharmaEngine, which provided for the development and commercialization of NBTXR3 by PharmaEngine throughout the covered Asia-Pacific countries. In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. During the six month period ended June 30, 2021, the Company paid a cumulative amount of $6.5 million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1 million upon receipt by the Company of certain clinical study reports and of $5 million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. As of June 30, 2021, these future payments were not accrued because the triggering events have not occurred. 4.2 LIANBIO In May 2021, Nanobiotix announced a partnership with LianBio a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations. As of June 30, 2021, a non-refundable upfront payment of $20 million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. See Note 15 Revenues and other income. 4.3 FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK (“EIB”) In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to €40 million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period, beginning as of June 30, 2022 based on the 2021 revenue) royalties to EIB. (See. Note 12 Financial liabilities). 4.4 COLLABORATION AGREEMENT WITH MD ANDERSON In January 2019, the Company and the University of Texas MD Anderson Cancer Center announced a large-scale research collaboration. The collaboration will support multiple Phase I/II clinical trials involving around 340 patients with NBTXR3 for use in treating several cancer types, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for those clinical trials during the collaboration. An additional milestone payment will also be paid upon grant of the first regulatory approval by the Food and Drug Administration in the United States. See Note 21 Commitments.

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2021
Intangible assets other than goodwill [abstract]
Intangible assets	Intangible assets The change in intangible assets breaks down as follows: (in thousands of euros) As of December 31, 2020 Increases Decreases Transfer As of June 30, 2021 Patents 65 — — — 65 Software 651 4 — — 656 Intangible assets in progress — — — — — Gross book value of intangible assets 717 4 — — 721 Patents (65) — — — (65) Software (630) (14) — — (644) Accumulated depreciation of intangible assets (1) (695) (14) — — (709) Net book value of intangible assets 21 (10) — — 12 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses No impairment losses were recognized in application of IAS 36 - Impairment of Assets

Property, plant and equipment

Property, plant and equipment	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Property, plant and equipment	Property, plant and equipment The change in property, plant and equipment is as follows: (in thousands of euros) As of December 31, 2020 Increases Decreases Other movements & transfer. Currency As of June 30, 2021 Fixtures, fittings and installations 3,313 — — — — 3,313 Right of use – Buildings 7,171 19 — — — 7,190 Technical equipment 2,061 5 — 1 — 2,067 Office and IT equipment 988 41 (1) — 2 1,029 Transport equipment 31 — — — 1 32 Right of use – Transport equipment 65 — — — 1 66 Tangible assets in progress 1 — — (1) — 1 Gross book value of tangible assets 13,630 65 (1) — 4 13,698 Fixtures, fittings and installations (1,320) (160) — — — (1,481) Right of use – Buildings (1,739) (457) — — — (2,196) Technical equipment (1,466) (93) — — — (1,559) Office and IT equipment (783) (67) 1 — (1) (850) Transport equipment (31) — — — (1) (32) Right of use – Transport equipment (36) (10) — — (1) (46) Accumulated depreciation of tangible assets (1) (5,374) (787) 1 — (2) (6,163) Net book value of tangible assets 8,256 (722) (1) — 1 7,535

Non-current financial assets

Non-current financial assets	6 Months Ended
	Jun. 30, 2021
Disclosure of financial assets [abstract]
Non-current financial assets	Non-current financial assets The change in non-current financial assets breaks down as follows: (in thousands of euros) Liquidity contract - Cash account (1) Other long- Security Total Net book value as of December 31, 2019 131 — 399 529 Additions — — 9 9 Decreases (27) — (5) (31) Currency translation adjustments — — (2) (2) Net book value as of December 31, 2020 105 — 401 505 Additions — — — — Decreases (16) — — (16) Reclassifications — — 8 8 Currency translation adjustments — — 1 1 Net book value as of June 30, 2021 88 — 410 498 (1) See Note 10.2 Treasury shares The decrease of the liquidity contract – cash account corresponds to the balance of treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of changes in shareholders’ equity.

Trade receivables and other cur

Trade receivables and other current assets	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables and other current assets	Trade receivables and other current assets 8.1 TRADE RECEIVABLES Trade receivables relate mainly to invoices issued to PharmaEngine in connection with the charging-back of shared external clinical research organization costs under the Company’s license and collaboration agreement with PharmaEngine. As of June 30, 2021, trade receivables have been settled following the termination of the collaboration contract between Nanobiotix and PharmaEngine. (See Note 4 Significant transactions for more detail on the license and collaboration agreement). As of (in thousands of euros) June 30, 2021 December 31, 2020 Trade receivables — 62 Trade receivables — 62 8.2 OTHER CURRENT ASSETS Other current assets break down as follows: As of (in thousands of euros) June 30, 2021 December 31, 2020 Research tax credit receivable 3,154 1,927 VAT receivable 1,129 971 Prepaid expenses 7,246 2,217 Other receivables 2,004 920 Other current assets 13,534 6,035 As of June 30, 2021, prepaid expenses mainly relate to research agreements for €7.2 million, including €4.4 million related to the Irish company ICON plc research agreement and €1.3 million related to MD Anderson agreement (see Note 4.4 Collaboration agreement with MD Anderson). As of December 31, 2020, prepaid expenses mainly related to the MD Anderson research agreement for €1.6 million. Other receivables mainly comprised advances paid to suppliers in the amounts of €1.4 million as of June 30, 2021, as compared to €805 thousand as of December 31, 2020. Research tax credit The change in research tax credit receivables breaks down as follows: (in thousands of euros) Receivable as of December 31, 2020 1,927 2021 research tax credit – Nanobiotix S.A. (1) 1,227 Receivable as of June 30, 2021 3,154 (1) See Note 15 Revenues and other income.

Cash and cash equivalents

Cash and cash equivalents	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalent break down as follows: As of (in thousands of euros) June 30, 2021 December 31, 2020 Cash and bank accounts 102,336 119,151 Net cash and cash equivalents 102,336 119,151

Share Capital

Share Capital	6 Months Ended
	Jun. 30, 2021
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]
Share Capital	Share Capital 10.1 CAPITAL ISSUED Detail of share capital transactions (in thousands or number of shares) Nature of transaction Share Capital Premiums related to share capital Number of shares December 31, 2020 1,033 255,735 34,432,122 March 31, 2021 Capital increase AGA 2018-1 1 (1) 24,500 March 31, 2021 Capital increase AGA 2019-1 11 (11) 369,250 May 31, 2021 Subscription of 2021 warrants — 43 — June 30, 2021 Other movements — 16 — June 30, 2021 1,045 255,782 34,825,872 As of June 30, 2021, the share capital was €1,045 thousand divided into 34,825,872 fully paid up ordinary shares each with a par value of €0.03. 10.2 TREASURY SHARES On June 30, 2021, the Company held 15,053 treasury shares under a liquidity contract entered into on October 23, 2012 with Gilbert Dupont as amended on November 30, 2018. These shares were deducted from IFRS equity in the amount of €212 thousand as of June 30, 2021. 10.3 FOUNDER’S WARRANTS, WARRANTS, STOCK OPTIONS AND FREE SHARES As of June 30, 2021, there are four different types of securities and other valid instruments entitling their holders to a stake in the Company's share capital: warrant (bons de souscription d’actions or BSA), founders’ warrant (bons de souscription de parts de créateur d’entreprise or BSPCE), stock option (options de souscription ou d’achat d’actions or OSA) and free shares (actions attribuées gratuitement or AGA). Warrants At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company’s shareholders' meeting held on November 30, 2020 granted 48,103 warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.47 (share premium included). The designated warrants included 18,103 warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period is open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of June 30, 2021, 14,431 warrants have been subscribed by their beneficiaries. The warrants can be exercised at any time during a 10-year period, subject to the satisfaction of the following conditions: • the subscription by the relevant beneficiary of his/her warrant • the relevant holder has attended at least 75% of the Supervisory Board meetings held during the twelve months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group, and • the recommended dose for two out of the three patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan. It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control. At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted 30,000 warrants to a consultant of the Company, each warrant giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.64 (share premium included) at any time during a ten-year period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of June 30, 2021, no warrants have been subscribed by the beneficiary. In addition, as of June 30, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet. Stock options At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company’s shareholders’ meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board 571,200 stock options (including 143,200 stock options and 428,000 performance stock options), each giving its holder the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €13.74 (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company’s annual shareholders’ meeting held on April 28, 2021 (the “ 2020 Stock Option Plan ”). The ordinary stock options are exercisable as follows: ▪ up to one-third of the ordinary stock options as from April 20, 2022; ▪ an additional one-third of the ordinary stock options as from April 20, 2023, ▪ the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case, ▪ no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this ten-year period will be forfeited by law. The performance stock options may be exercised under the following conditions: ▪ 10% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €24.00, ▪ an additional 10% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €30.00, ▪ an additional 40% of the stock options may be exercised when the market price of the Company’s shares on the regulated market of Euronext in Paris reaches €40.00, ▪ an additional 40% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches €60.00, and ▪ at the latest within 10 years of the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law. It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such performance stock options as from April 20, 2022, (y) an additional 30% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., 60% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number. At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders’ meeting held on November 30, 2020 granted 60,000 ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company’s annual shareholders’ meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn 60,000 performance stock options governed by such plan. Each of such 120,000 stock options (whether ordinary and performance) gives it holders the right to subscribe one ordinary share, each with a par value of €0.03 and at a price of €12.99 (share premium included). The exercise conditions of the 143,200 ordinary stock options and 428,000 performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these 60,000 ordinary stock options and 60,000 performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for two of the three patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology. Free Shares At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company’s shareholders’ meeting on November 30, 2020, granted 362,515 free shares, each with a par value of €0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021. Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology. As of June 30, 2021, the assumptions related to the estimated vesting of the founders’ warrants, the warrants and performance stock options issued in 2016 have been updated (See Note 17 Share-based payments).

Provisions

Provisions	6 Months Ended
	Jun. 30, 2021
Provisions [abstract]
Provisions	Provisions Details of provisions (in thousands of euros) As of December 31, 2020 Increases Decreases (1) As of June 30, 2021 Lump-sum retirement benefits 414 42 — 457 Non-current provisions 414 42 — 457 Provisions for disputes 40 390 — 430 Provision for charges — — — — Current provisions 40 390 — 430 Total provisions 454 432 — 887 (1) See Statement of consolidated cash flows and Note 16.4 Depreciation, amortization and provision expenses for the nature of these decreases 11.1 CURRENT PROVISIONS During the first half of 2021, Nanobiotix S.A. initiated proceedings against an employee regarding strategic misalignment. A conciliation agreement is currently being negotiated between the parties, providing for the payment of a total settlement of €390 thousand, accrued entirely as of June 30, 2021. 11.2 NON-CURRENT PROVISIONS Commitments for retirement benefits As of (in thousands of euros) June 30, 2021 December 31, 2020 Provision as of beginning of period 414 331 Cost of services 42 76 Discounting costs 1 3 Expense for the period 43 79 Actuarial gains or losses recognized in other comprehensive income — 4 Provision as of the end of period 457 414 The assumptions used to measure lump-sum retirement benefits are as follows: Measurement date June 30, 2021 December 31, 2020 Retirement assumptions Executive: Age 66 Non-Executive: Age 64 Executive: Age 66 Non-Executive: Age 64 Social security contribution rate 44 % 44 % Discount rate 0.33 % 0.33 % Mortality tables Regulatory table Regulatory table Salary increase rate (including inflation) Executive: 3% Non-Executive: 2.5% Executive: 3% Non-Executive: 2.5% Staff turnover Constant average rate of 5.86% Constant average rate of 5.86% Duration 17 years 17 years The rights granted to Company employees are defined in the collective agreement for the pharmaceutical industry (manufacturing and sales of pharmaceutical products).

Financial liabilities

Financial liabilities	6 Months Ended
	Jun. 30, 2021
Disclosure of financial liabilities [abstract]
Financial liabilities	Financial liabilities Details of financial liabilities As of (in thousands of euros) June 30, 2021 December 31, 2020 Lease liabilities – Short term 714 1,197 Repayable advances OSEO/Bpifrance loan – Short term 500 500 PGE* 208 141 EIB loan – Short term 5,308 3,033 Total current financial liabilities 6,730 4,872 Lease liabilities – Long term 4,851 4,991 Repayable OSEO/Bpifrance loan advances – Long term 2,768 2,975 PGE* 9,927 9,922 EIB loan – Long term 26,441 26,218 Total non-current financial liabilities 43,988 44,107 Total financial liabilities 50,718 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Bpifrance and OSEO conditional advances The Company receives repayable advances from Banque Publique d’Investissement (“ Bpifrance ”, formerly known as OSEO Innovation). The advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for 18 months. The amount to be reimbursed corresponds to the amount received to date, €2.1 million, increased by the interest amount (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities). In June 2020, Curadigm SAS obtained a €500 thousand conditional advance from Bpifrance, €350 thousand of which was received at the signature date while the remaining amount will be received by Curadigm upon completion of the work, as of March 1, 2022 at the latest. As of June 30, 2021, the work had not been completed and the balance, therefore, has not been paid. EIB loan In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of €40 million, divided in three tranches. The first tranche, with a nominal value of €16 million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of €14 million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due. The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company yet. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. Pursuant to the terms of the EIB loan, the Company is also required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.3 Financing agreement with the EIB). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 Financial liabilities for details about the impact of this sales forecast update). A 10% increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of June 30, 2021. PGE loan On June 5, 2020, the Company announced that it had received approval from HSBC and Bpifrance for a total of €10 million of non-dilutive financing in the form of PGEs (State Guaranteed Loans). The French government guarantees 90% of the amounts due under each of these PGEs. On June 22, 2020, the Company received the first half of the €5 million PGE financing from HSBC France. This loan has a term of 6 years and is 90% guaranteed by the French government. The loan is interest-free for the first 12-month period, but at the end of this period and for the following 5 years, it will bear an interest rate of 0.31% per annum and a guarantee fee of 0.5% (rising to 1% in the last three years). The Company has requested for an extension of the deferral of the principal repayment starting date for an additional 12 months period. The interest and principal of the HSBC loan will be repaid in 20 and 16 quarterly installments, respectively, starting September 22, 2021 and September 22, 2022 and ending July 26, 2026. On July 10, 2020, the Company entered into the second €5 million PGE loan agreement with Bpifrance (the ‘‘Bpifrance PGE Loan’’). The Bpifrance PGE loan has a six-year term and is 90% guaranteed by the French government. The Bpifrance PGE loan will bear no interest for the first 12-month period but, following such 12-month period and for the subsequent 5 years, will bear an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in 20 quarterly installments as from October 31, 2021 until July 26, 2026. Lease Liabilities Lease liabilities correspond to the discounted amount of the rentals to be paid over the lease terms for all outstanding contracts falling within the scope of IFRS 16. For the period presented, the main contracts relate to the buildings rented in Paris. Note 12.2 Lease liabilities below presents the lease liability and the related liability increases or decreases recorded during the period. 12.1 CONDITIONAL ADVANCE, BANK LOAN AND LOANS FROM GOVERNMENT AND PUBLIC AUTHORITIES The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities: Conditional advances, interest-free loans from government and public authorities (in thousands of euros) Bpifrance advance Interest-free Bpifrance loan Curadigm Bpifrance advance EIB loan Total As of December 31, 2020 2,216 974 285 29,251 32,727 Impact of discounting and accretion 9 11 8 4 31 Accumulated fixed interest expense accrual 16 — — 889 906 Accumulated variable interest expense accrual — — — 1,955 1,955 Repayment — (250) — (350) (600) As of June 30, 2021 2,241 735 292 31,749 35,018 Bank loans (in thousands of euros) HSBC Bpifrance “PGE” Total As of December 31, 2020 5,020 5,044 10,064 Impact of discounting and accretion 22 42 64 Accumulated fixed interest accrual (3) 11 8 As of June 30, 2021 5,039 5,096 10,136 12.2 LEASE LIABILITIES The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the six month period ended June 30, 2021: (in thousands of euros) Lease liabilities As of December 31, 2020 6,189 New lease contracts 22 Impact of discounting of the new lease contracts (3) Fixed interest expense 152 Repayment of lease (796) As of June 30, 2021 5,564 12.3 DUE DATES OF THE FINANCIAL LIABILITIES The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows: As of June 30, 2021 (in thousands of euros) Less than 1 year Between 1 and Between 3 and More than 5 years Total Bpifrance — 800 1,608 — 2,408 Interest-free Bpifrance loan 500 250 — — 750 Curadigm interest-free Bpifrance advance — 125 200 25 350 HSBC “PGE” (1) 40 2,572 2,545 — 5,157 Bpifrance “PGE” (1) 168 2,320 2,620 327 5,435 EIB fixed rate loan 5,308 31,328 — — 36,637 Lease liabilities 988 2,314 2,309 821 6,432 Total 7,004 39,710 9,282 1,173 57,169 (1) The Company plans to reimburse the two “PGE”or (“Prêts garantis par l’Etat” or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below. The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of June 30, 2021.

Trade payables and other curren

Trade payables and other current liabilities	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade payables and other current liabilities	Trade payables and other current liabilities 13.1 TRADE AND OTHER PAYABLES Details of trade and other payables As of (in thousands of euros) June 30, 2021 December 31, 2020 Accrued expenses - clinical trials 1,572 1,532 Other trade payables 7,241 5,574 Total trade and other payables 8,813 7,106 Trade payables are not discounted, as none of the amounts were due in more than one year. 13.2 OTHER CURRENT LIABILITIES As of (in thousands of euros) June 30, 2021 December 31, 2020 Tax liabilities 305 283 Payroll tax and other payroll liabilities 4,807 6,248 Other payables 398 491 Other current liabilities 5,510 7,022 Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer withholdings relating to free shares, accrued bonuses, vacation days and related social charges. 13.3 DEFERRED REVENUES AND CONTRACT LIABILITIES As of (in thousands of euros) June 30, 2021 December 31, 2020 Deferred revenues and contract liabilities 16,555 — Deferred revenues and contract liabilities 16,555 — Change in deferred revenues and contract liabilities as of June 30, 2021 consists of contract liabilities relating to the LianBio contract in the amount of €16.6 million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details.

Financial instruments included

Financial instruments included in the statement of financial position and impact on income	6 Months Ended
	Jun. 30, 2021
Disclosure of detailed information about financial instruments [abstract]
Financial instruments included in the statement of financial position and impact on income	Financial instruments included in the statement of financial position and impact on income Detail of financial instruments included in the statements of financial position and impact on income As of June 30, 2021 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 498 88 410 498 Trade receivables — — — — Cash and cash equivalents 102,336 — 102,336 102,336 Total assets 102,834 88 102,747 102,834 Financial liabilities Non-current financial liabilities 43,988 — 43,988 43,988 Current financial liabilities 6,730 — 6,730 6,730 Trade payables and other payables 8,813 — 8,813 8,813 Total liabilities 59,531 — 59,531 59,531 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value. Management of financial risks The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. The principal risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks. Liquidity risk Given the amount of cash and cash equivalents held by the Company as of June 30, 2021 (see Note 9 Cash and cash equivalents), the Company does not believe that it is exposed to short-term liquidity risk. Foreign Currency Exchange Risk The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone. At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks. Credit risk Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of June 30, 2021 and in part to its customers’ high credit rating for other receivables. Interest rate risk The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated. In 2018 the Company entered into an agreement with the EIB pursuant to which the Company may borrow a total of up to €40 million, divided in three tranches, two of which were received through June 30, 2021. In addition to the fixed interest rate, the Company also committed, for a period lasting from 2022 to 2027 to pay additional interest in the form of royalties indexed to the Company’s annual sales turnover beginning on January 1, 2021. Because the interest rate on the loan does not depend on market performance, the exposure of the Company to interest rate and market risk is deemed low. A 10% increase of the estimated future revenues would result in an immaterial change in the value of the debt recognized under the contract with the EIB at June 30, 2021 (see Note 4.3 Financing agreement with the EIB). Fair value The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date. The carrying value of receivables and current liabilities is assumed to approximate their fair value.

Revenues and other income

Revenues and other income	6 Months Ended
	Jun. 30, 2021
Revenue [abstract]
Revenues and other income	Revenues and other income The revenue recognition accounting principles used to prepare the interim condensed consolidated financial statements for the six month period ended June 30, 2021 are identical to those used for the year ended December 31, 2020. However, the information related to the new license and collaboration agreement with LianBio is presented below. Application of IFRS 15 to the license and collaboration agreement with PharmaEngine The application of IFRS 15 to the license and partnership agreement entered into in 2012 between the Company and PharmaEngine is presented in section 4.1.6.15 of the Company's universal reference document filed with the Autorité des marchés financiers ("AMF") on April 7, 2021 and in the Note 15 of the Consolidated financial statements as of and for the year ended December 31, 2021 included in the Form 20-F, as amended, filed to the Securities and Exchange Commission ("SEC) the same day. In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions. Application of IFRS 15 to the license and collaboration agreement with LianBio Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15 as the license, development services and product revenues are revenues of the Company. We identified the separate performance obligations of the contract under IFRS 15. The partnership includes the following obligations to LianBio: • an exclusive license, under the Company's intellectual property, to develop and market the licensed products, • the right to actively participate in global Phase III registration trials to obtain marketing approval in China, • if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals, • if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial, and • the requirement to purchase products under license to the Company. The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct. As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone. LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases. Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products. In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts. No revenue is to be recognized when such a right is granted. The upfront payment and milestone payment are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products. The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined. Grants Since its creation, the Company has received, because of its innovative approach to nanomedicine, certain grants and subsidies from the French State or French public authorities. These grants and subsidies are intended to finance its general or specified activities. Grants are recognized as income as the related expenses are incurred, irrespective of whether they are actually received. Research tax credit The research tax credit ("CIR") is granted to companies by the French government to encourage them to conduct technical and scientific research. Companies that can prove that they have incurred expenses that meet the required criteria (research expenses located in France or, since January 1, 2005, in the European Community or in another country that is a party to the Agreement on the European Economic Area and that has entered into a tax treaty with France containing an administrative assistance clause) are entitled to a tax credit which, in principle, can be offset against the corporate income tax due for the fiscal year in which the expenses were incurred and for the three The Company has benefited from the research tax credit since its creation. This financing is recorded under "Other income" in the year in which the corresponding expenses were incurred. The portion of the financing related to capitalized expenses is deducted in the balance sheet from the capitalized expenses and in the income statement from the amortization expenses of these expenses. Detail of revenues and other income The following table summarizes the Company’s revenues and other income per category for the six month period ended June 30, 2021 and 2020: For the six month period ended June 30, (in thousands of euros) 2021 2020 Services 5 37 Other sales 5 — Total revenues 10 37 Research tax credit 1,227 888 Subsidies 62 494 Other 20 28 Total other income 1,309 1,411 Total revenues and other income 1,319 1,448 The €432 thousand decrease in subsidies between June 30, 2021 and June 30, 2020 is mainly related to the subsidies granted by the French State in 2020 to compensate for limitations on activity implemented during the COVID-19 pandemic.

Operating expenses

Operating expenses	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Operating expenses	Operating expenses 16.1 RESEARCH AND DEVELOPMENT EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Purchases, sub-contracting and other expenses (9,386) (7,096) Payroll costs (including share-based payments) (5,105) (5,397) Depreciation, amortization and provision expenses (1) (1,015) (583) Total research and development expenses (15,506) (13,077) (1) see Note 16.4 Depreciation, amortization and provision expenses Purchases, sub-contracting and other expenses increased by €2.3 million for the six month period ended June 30, 2021 as compared with the same period in 2020. This increase reflects the impact of the COVID-19 pandemic in 2020 and the Company's focus on advancing its clinical trial development priorities, specifically the global phase III registrational trial (NANORAY-312). 16.2 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Purchases, fees and other expenses (5,152) (2,955) Payroll costs (including share-based payments) (4,848) (3,641) Depreciation, amortization and provision expenses (1) (176) (159) Total SG&A expenses (10,176) (6,755) (1) see Note 16.4 Depreciation, amortization and provision expenses Purchases, fees and other expenses increased by €2.2 million for the six month period ended June 30, 2021 as compared with the same period in 2020 and mainly relate to legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a US public company as well as recruitment expenses. SG&A payroll costs increased by 33%, an increase of €1.2 million. This increase is mainly due to an increase of headcount, the indemnity payment related to Mr. Mauberna (See Note 1 Company information) and the 2020 partial unemployment measure issued by the French government reducing prior year payroll cost. 16.3 PAYROLL COSTS For the six month period ended June 30, (in thousands of euros) 2021 2020 Wages and salaries (5,939) (5,658) Payroll taxes (2,574) (1,799) Share-based payments (1,398) (1,542) Retirement benefit obligations (42) (38) Total payroll costs (9,953) (9,038) Average headcount 93 104 End-of-period headcount 98 98 As of June 30, 2021, the Company had 98 employees, including 70 in R&D and 28 in selling, general and administrative expenses, compared to 98 as of June 30, 2020. In the first half of 2021, salaries and payroll taxes increased by 15%, or by €1.1 million, mainly as a result of the partial unemployment measure in 2020 and severance payments in the first half of 2021. In accordance with IFRS 2 – Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to €1.4 million for the six month period ended June 30, 2021, as compared with €1.5 million as of June 30, 2020 (see Note 17 Share-based payments). 16.4 DEPRECIATION, AMORTIZATION AND PROVISION EXPENSES Depreciation, amortization and provision expenses by function are detailed as follows: For the six month period ended June 30, 2021 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (23) (2) (25) Amortization expense of tangible assets (602) (174) (776) Provision for charges (390) — (390) Total depreciation, amortization and provision expenses (1,015) (176) (1,191) For the six month period ended June 30, 2020 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (73) (44) (117) Amortization expense of tangible assets (623) (167) (789) Reversal of provision for disputes 112 52 164 Total depreciation, amortization and provision expenses (583) (159) (742) 16.5 OTHER OPERATING INCOME AND EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Contract termination indemnities (PharmaEngine) 5,414 — Total Other operating income and expenses 5,414 — The Company has made payments for a cumulative amount of $6.5 million (€5.4 million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.1 PharmaEngine.

Share-based payments

Share-based payments	6 Months Ended
	Jun. 30, 2021
Share-based Payments Arrangements [Abstract]
Share-based payments	Share-based payments Detail of share-based payments The Company has granted stock options, warrants, founders’ warrants and free shares to corporate officers, employees, members and observers of the Supervisory Board and consultants of the Group. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash. The number of options and warrants outstanding on June 30, 2021 and their main characteristics, are detailed below: Founders’ warrants BSPCE 2012-2 BSPCE 08-2013 BSPCE 09-2014 BSPCE 2015-1 BSPCE 2015-3 Date of the shareholders' meeting 4-May-12 28-Jun-13 18-Jun-14 18-Jun-14 18-Jun-14 Date of grant by the Executive Board 18-dec-12 28-Aug-13 16-Sep-14 10-Feb-15 10-Jun-15 Total number of BSPCEs authorized 500,000 500,000 450,000 450,000 450,000 Total number of BSPCEs granted 100,000 50,000 97,200 71,650 53,050 Total number of shares to which the BSPCE were likely to give right on the date of their grant 100,000 50,000 97,200 71,650 53,050 the number of which that may be subscribed by corporate officers: — — 21,000 24,000 — the number that can be subscribed by Laurent LEVY — — 21,000 24,000 — Number of beneficiaries who are not corporate officers 2 1 30 13 42 Starting date for the exercise of the BSPCE 12/18/12 08/28/13 09/16/15 02/10/2016 06/10/2016 BSPCE expiry date 12/18/22 08/28/23 09/16/24 02/10/2025 06/10/2025 BSPCE exercise price €6.63 €5.92 €18.68 €18.57 €20.28 Number of shares subscribed as of June 30, 2021 — — — — — Total number of BSPCEs lapsed or cancelled as of June 30, 2021 — — 11,050 3,200 22,350 Total number of BSPCEs outstanding as of June 30, 2021 100,000 50,000 86,150 68,450 30,700 Total number of shares available for subscription as of June 30, 2021 100,000 50,000 86,150 68,450 30,700 Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met) 100,000 50,000 86,150 68,450 30,700 BSPCE 2016 Ordinary BSPCE 2016 Performance BSPCE 2017 Ordinary BSPCE “2017” Date of the shareholders' meeting 25-Jun-15 25-Jun-15 23-Jun-16 23-Jun-16 Date of grant by the Executive Board 2-Feb-16 2-Feb-16 7-Jan-17 7-Jan-17 Total number of BSPCEs authorized 450,000 450,000 450,000 450,000 Total number of BSPCEs granted 126,400 129,250 117,650 80,000 Total number of shares to which the BSPCE were likely to give right on the date of their grant 126,400 129,250 117,650 80,000 the number of which that may be subscribed by corporate officers: 23,500 23,500 26,400 32,000 the number of which that may be subscribed by Laurent LEVY 23,500 23,500 26,400 32,000 Number of beneficiaries who are not corporate officers 43 50 42 3 Starting date for the exercise of the BSPCE 02/02/2017 02/02/2016 01/08/2018 01/07/2017 BSPCE expiry date 02/02/2026 02/02/2026 01/07/2027 01/07/2027 BSPCE exercise price €14.46 €14.46 €15.93 €15.93 Number of shares subscribed as of June 30, 2021 333 — — — Total number of BSPCEs lapsed or cancelled as of June 30, 2021 25,150 28,426 16,800 — Total number of BSPCEs outstanding as of June 30, 2021 100,917 100,824 100,850 80,000 Total number of shares available for subscription as of June 30, 2021 100,917 38,544 100,850 80,000 Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of said BSPCEs are met) 100,917 100,824 100,850 80,000 Warrants BSA 04-12 BSA 2013 BSA 2014 BSA 2015-1 BSA 2015-2 (a) BSA 2016-2 BSA 2017 Date of the shareholders’ meeting 4-May-12 4-May-12 18-Jun-14 18-Jun-14 18-Jun-14 23-Jun-16 23-Jun-16 Date of grant by the Executive Board 4-May-12 10-Apr-13 16-Sep-14 10-Feb-15 25-Jun-15 3-Nov-16 7-Jan-17 Maximum number of BSAs authorized 200,000 200,000 100,000 100,000 100,000 100,000 100,000 Total number of BSAs granted 52,500 10,000 14,000 26,000 64,000 8,000 18,000 Number of shares to which the BSA were likely to give right on the date of their grant 52,500 10,000 14,000 26,000 64,000 8,000 18,000 including the total number of shares that may subscribed by the corporate officers of the Company 22,500 — 8,000 15,000 — — 13,280 Relevant officers: Anne-Marie GRAFFIN 5,000 3,820 Enno SPILLNER 3,000 3,820 Alain HERRERA 4,000 5,000 2,820 Gary PHILLIPS Christophe DOUAT (observer) 22,500 4,000 2,000 2,820 Number of beneficiaries who are not corporate officers 1 1 1 2 1 2 1 Starting date for the exercise of the BSA 10/23/2013 04/30/2014 09/16/2014 02/10/2015 06/25/2015 11/03/2016 01/07/2017 BSA expiry date (6) 05/04/2022 04/10/2023 09/16/2024 02/10/2025 06/25/2025 11/03/2021 01/07/2022 BSA issue price €0.60 €2.50 €4.87 €4.87 €5.00 €2.03 €2.26 Exercise price per BSA €6.00 €6.37 €17.67 €17.67 €19.54 €15.01 €15.76 Number of shares subscribed as of June 30, 2021 22,500 — — — — — — Total number of forfeited or cancelled BSAs as of June 30, 2021 — 4,000 4,000 5,000 — — — Total number of BSAs outstanding as of June 30, 2021 30,000 6,000 10,000 21,000 64,000 8,000 18,000 Total number of shares available for subscription as of June 30, 2021 (considering the conditions of exercise of the BSAs) 30,000 6,000 — — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met) 30,000 6,000 10,000 21,000 64,000 8,000 18,000 BSA 2018 BSA 2018-1 BSA 2018-2 BSA 2019-1 BSA 2020 BSA 2021 (a) BSA 2021 (b) Date of the shareholders’ meeting 14-Jun-17 14-Jun-17 23-May-18 23-May-18 11-Apr-19 30-Nov-20 30-Nov-20 Date of grant by the Executive Board 6-Mar-18 6-Mar-18 27-Jul-18 29-Mar-19 17-Mar-20 20-Apr-21 20-Apr-21 Maximum number of BSAs authorized 116,000 116,000 140,000 140,000 500,000 650,000 650,000 Total number of BSAs granted 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Number of shares to which the BSA were likely to give right on the date of their grant 18,000 10,000 5,820 18,000 18,000 48,103 30,000 including the total number of shares that may subscribed by the corporate officers of the Company 12,700 — — 12,700 14,024 33,672 — Relevant officers: Anne-Marie GRAFFIN 2,900 2,900 3,843 8,500 Enno SPILLNER 4,000 4,000 3,829 8,200 Alain HERRERA 2,900 2,900 3,195 9,227 Gary PHILLIPS Christophe DOUAT (observer) 2,900 2,900 3,157 7,745 Number of beneficiaries who are not corporate officers 1 1 1 1 1 1 1 Starting date for the exercise of the BSA 03/06/2018 03/06/2018 07/27/18 03/29/19 03/17/20 04/20/21 04/20/21 BSA expiry date (6) 03/06/2023 03/06/2023 07/27/28 03/29/29 03/17/30 04/20/31 04/20/31 BSA issue price €1.62 €1.62 €2.36 €1.15 €0.29 €2.95 €0.68 Exercise price per BSA €13.55 €13.55 €16.10 €11.66 €6.59 €13.47 €13.64 Number of shares subscribed as of June 30, 2021 — — — — — — — Total number of forfeited or cancelled BSAs as of June 30, 2021 — — — — — — — Total number of BSAs outstanding as of June 30, 2021 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Total number of shares available for subscription as of June 30, 2021 (considering the conditions of exercise of the BSAs) — — — — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met) 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Stock options OSA 2016-1 Performance OSA 2016-2 OSA 2017 Ordinary OSA 2018 OSA 2019-1 OSA 2019 LLY Date of the shareholders’ meeting 25-Jun-15 23-Jun-16 23-Jun-16 14-Jun-17 23-May-18 11-Apr-19 Date of grant by the Executive Board 02-Feb-16 03-Nov-16 07-Jan-17 6-Mar-18 29-Mar-19 24-Oct-19 Total number of OSAs authorized 450,000 450,000 450,000 526,800 648,000 650,000 Total number of OSAs granted 6,400 4,000 3,500 62,000 37,500 500,000 Total number of shares to which the OSAs were likely to give right on the date of their grant 6,400 4,000 3,500 62,000 37,500 500,000 including the number that may be subscribed or purchased by corporate officers: — — — — — 500,000 the number that can be subscribed by Laurent LEVY 500,000 the number that can be subscribed by Anne-Juliette HERMANT the number that can be subscribed by Bart VAN RHIJN Number of beneficiaries who are not corporate officers 2 1 2 5 12 — Starting date for the exercise of the OSA 02/02/2017 11/03/2017 01/08/2018 03/07/2019 03/30/2021 10/24/2019 OSA expiry date 02/02/2026 11/03/2026 01/07/2027 03/06/2028 03/29/2029 10/24/2029 Exercise price per OSA €13.05 €14.26 €14.97 €12.87 €11.08 €6.41 Number of shares subscribed as of June 30, 2021 — — — — — — Total number of lapsed or cancelled OSAs as of June 30, 2021 6,000 — 3,000 10,000 8,750 — Total number of OSAs outstanding as of June 30, 2021 400 4,000 500 52,000 28,750 500,000 Maximum number of shares available for subscription as of June 30, 2021 (given the vesting conditions of the OSAs) 120 4,000 500 52,000 19,165 — Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met) 400 4,000 500 52,000 28,750 500,000 OSA 2020 OSA 2021-04 Ordinary OSA 2021-04 Performance OSA 2021-06 Performance OSA 2021-06 Ordinary Date of the shareholders’ meeting 11-Apr-19 30-Nov-20 30-Nov-20 30-Nov-20 28-Apr-21 Date of grant by the Executive Board 11-Mar-20 20-Apr-21 20-Apr-21 21-Jun-21 21-Jun-21 Total number of OSAs authorized 650,000 850,000 1,000,000 1,000,000 850,000 Total number of OSAs granted 407,972 143,200 428,000 60,000 60,000 Total number of shares to which the OSAs were likely to give right on the date of their grant 407,972 143,200 428,000 60,000 60,000 including the number that may be subscribed or purchased by corporate officers: 180,000 — 240,000 60,000 60,000 the number that can be subscribed by Laurent LEVY 120,000 180,000 the number that can be subscribed by Anne-Juliette HERMANT 60,000 60,000 the number that can be subscribed by Bart VAN RHIJN 60,000 60,000 Number of beneficiaries who are not corporate officers 104 13 14 — — Starting date for the exercise of the OSA 03/11/2021 04/20/22 04/20/22 06/21/22 06/21/22 OSA expiry date 03/11/2030 04/20/31 04/20/31 06/21/31 06/21/31 Exercise price per OSA €6.25 €13.74 €13.74 €12.99 €12.99 Number of shares subscribed as of June 30, 2021 — — — — — Total number of lapsed or cancelled OSAs as of June 30, 2021 14,298 — — — — Total number of OSAs outstanding as of June 30, 2021 393,674 143,200 428,000 60,000 60,000 Maximum number of shares available for subscription as of June 30, 2021 (given the vesting conditions of the OSAs) 172,147 — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met) 393,674 143,200 428,000 60,000 60,000 Free shares AGA 2018-1 AGA 2018-2 AGA 2019-1 AGA 2020 AGA 2021 Date of the shareholders’ meeting 14-Jun-17 23-May-18 23-May-18 11-Apr-19 30-Nov-20 Date of grant by the Executive Board 6-Mar-18 27-Jul-18 29-Mar-19 11-Mar-20 20-Apr-21 Total number of AGAs authorized 526,800 648,000 648,000 650,000 850,000 Total number of AGAs granted 396,250 6,000 438,250 50,000 362,515 Total number of shares to which the AGAs were likely to give right on the date of their grant 396,250 6,000 438,250 50,000 362,515 including the number that can be subscribed by corporate officers: 77,500 — 150,000 50,000 270,000 the number that can be subscribed by Laurent LEVY 77,500 — 150,000 — 180,000 the number that can be subscribed by Anne-Juliette HERMANT — — — 50,000 90,000 Number of beneficiaries who are not corporate officers 78 1 80 — 79 Date of acquisition (end of the acquisition period) (1) 07/27/20 (2) 03/11/22 04/20/23 Number of shares subscribed as of June 30, 2021 340,583 6,000 369,250 — — Total number of AGAs lapsed or cancelled as of June 30, 2021 55,667 — 69,000 — 2 Total number of AGAs outstanding as of June 30, 2021 — — — 50,000 362,513 Total number of shares that may be subscribed — — — 50,000 362,513 Duration of the holding period (1) 1 year (2) 1 year 1 year (1) The AGA2018-1 granted to French tax residents were definitely acquired on March 6, 2020 were subject to a one-year holding period ending on March 6, 2021. The AGA2018-1 granted to foreign tax residents were definitely acquired on March 6, 2021 and will not be subject to any holding period. (2) The AGA2019-1 granted to French tax residents were definitely acquired on March 29, 2021 and will then be subject to a one-year holding period ending on March 29, 2022. The AGA2019-1 granted to foreign tax residents will be definitely acquired on March 29, 2022 and will not be subject to any holding period. BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of June 30, 2021 717,891 304,923 1,670,524 412,513 3,105,851 The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below: • The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at €40, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company; • The risk-free rate was determined based on the average life of the instruments; and • Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option. The performance conditions for all of the plans were assessed as follows: • Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and • Market-related performance conditions were directly included in the calculation of the fair value of the instruments. As of June 30, 2021, the assumptions concerning the probability that the performance conditions of the 2016 BSPCE, BSA and OSA have been updated. Except for the 2012-1 founders’ warrants, the fair value of the warrants and options was measured using the Black-Scholes model. The fair value of 2012-1 founders’ warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. The data used for the estimation and measurement of new awards and ongoing awards are detailed below: BSPCE Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) BSPCE 2012-1 5.26 5.26 41 % 3.49 0.20 % 0.00 % 307 — — BSPCE 2012-2 6.65 6.63 44.3% - 47.6% 5 - 7.30 0.84% - 1.22% 0.00 % 288 — — BSPCE 04-2013 6.30 6.30 56 % 5 0.90 % 0.00 % 167 — — BSPCE 08-2013 6.30 5.92 256 % 7 0.90 % 0.00 % 152 — — BSPCE 09-2014 18.68 18.68 58 % 5.5/6/6.5 0.64 % 0.00 % 932 — — BSPCE 2015-2 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 650 — — BSPCE 2015-3 20.28 20.28 61% - 62% - 61% 5.5/6/6.5 0.56 % 0.00 % 483 — — BSPCE 2016 Ordinary 14.46 14.46 59% - 62% - 60% 5.5/6/6.5 0.32 % 0.00 % 1,080 — — BSPCE 2016 Performance 14.46 14.46 59 % 5 0.19 % 0.00 % 1,212 5 63 BSPCE 2017 Ordinary 15.93 15.93 58% - 61% - 59% 5.5/6/6.5 0.23 % 0.00 % 1,000 — 8 BSPCE 2017 Performance 15.93 15.93 59 % 5 0.11 % 0.00 % 622 — — BSPCE 2017 15.93 15.93 59 % 5 0.11 % 0.00 % 627 — — BSPCE 2017 Project 15.93 15.93 59 % 5 0.11 % 0.00 % 94 — — Total BSPCE n.a. n.a. n.a. n.a. n.a. n.a. n.a. 5 71 BSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) BSA 04-2012 6.00 6.00 49 % 10 0.96 % 0.00 % 183 — — BSA 2013 6.30 6.37 156 % 6 0.90 % 0.00 % 1 — — BSA 2014 18.68 17.67 57 % 5 0.41 % 0.00 % — — — BSA 2015-1 17.67 17.67 58 % 5 0.26% - 0.27% 0.00 % 63 — — BSA 2015-2 (a) 17.67 19.54 58%-58%-57%-58% 5/5.1/5.3/5.4 0.39 % 0.00 % 16 — — BSA 2015-2 (b) 19.54 19.54 58% - 60% 4.6 – 9.6 0.25% - 0.91% 0.00 % 284 — — BSA 2016o 13.74 13.74 57 % 2.4 0.00 % 0.00 % 37 — — BSA 2016p 13.74 13.74 57 % 2.4 0.00 % 0.00 % 143 — — BSA 2016-2 15.01 15.01 57 % 2.4 0.00 % 0.00 % — — — BSA 2017 15.76 15.76 33 % 2.4 0.00 % 0.00 % — — — BSA 2018 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % 2 — — BSA 2018-1 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % — — — BSA 2018-2 16.10 16.10 38 % 4.8 0.7% - 0.1% 0.00 % 1 — — BSA 2019-1 11.66 11.66 37 % 9.8/9.9 0.16% - 0.50% 0.00 % 24 — — BSA 2020 13.03 6.59 38 % 10 -0.13%/ 0.00 % 19 — 19 BSA 2021 (a) 13.47 13.47 39.10 % 10 0.27 % 0.00 % 44 44 — BSA 2021 (b) n.a. 13.64 n.a. 10 n.a. 0.00 % — — — Total BSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 44 19 OSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) OSA 2016 Ordinary 13.05 13.05 59% - 62% - 60% 5.5 / 6 /6.5 0.32 % 0.00 % 117 — — OSA 2016 Performance 13.05 13.05 59 % 5 0.19 % 0.00 % 69 — — OSA 2016-2 14.26 14.26 58% - 62% - 59% 5.5 / 6 /6.5 0.04 % 0.00 % 27 — — OSA 2017 Ordinary 15.93 14.97 58% - 61% - 59% 5.5 / 6 /6.5 0.23 % 0.00 % 31 — — OSA 2017 Performance 15.93 14.97 59 % 5 0.11 % 0.00 % 35 — — OSA 2018 12.87 12.87 35 % 5.5 / 6 /6.5 0.00 % 0.00 % 252 — 6 OSA 2019-1 11.08 11.08 38.1% / 37.4% 6 /6.5 0.103% / 0.149% 0.00 % 140 13 27 OSA 2019-2 6.41 6.41 37 % 10 0.40 % 0.00 % 252 — — OSA 2020 6.25 6.25 38 % 10 0.31 % 0.00 % 939 225 172 OSA 2021-04 O 13.60 13.74 38.9% - 37.8% - 38.3 % 5.5 / 6 / 6.5 -0.38% / -0.33% / -0.28% 0.00 % 684 80 — OSA 2021-04 P 13.60 13.74 39.10 % 10 0.03 % 0.00 % 1,816 39 — OSA 2021-06 O 12.20 12.99 39.2% - 37.8% - 38.1% 5.5 / 6 / 6.5 -0.35% / -0.30% / -0.26% 0.00 % 246 4 — OSA 2021-06 P 12.20 12.99 39.10 % 10 0.13 % 0.00 % 212 5 — Total OSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 367 205 AGA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) AGA 2018-1 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 4,951 16 224 AGA 2018-2 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 75 — 19 AGA 2019-1 10.90 0.00 n.a. n.a. 0.19% / 0.141% 0.00 % 4,776 422 960 AGA 2020 5.90 0.00 n.a. n.a. -0.74%/ 0.00 % 287 71 43 AGA 2021 13.60 0.00 n.a. n.a. -0.63% / -0.59% 0.00 % 4,869 473 — Total AGA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 983 1,246 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2021 5 44 367 983 1,398 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2020 71 19 205 1,246 1,542

Net financial income (loss)

Net financial income (loss)	6 Months Ended
	Jun. 30, 2021
Net Financial Income (Loss) [Abstract]
Net financial income (loss)	Net financial income (loss) For the six month period ended June 30, (in thousands of euros) 2021 2020 Income from cash and cash equivalents — — Foreign exchange gains 2,511 177 Other financial income — 56 Total financial income 2,511 234 Interest cost (2,960) (2,219) IFRS 16 related interests (152) (169) Foreign exchange losses (39) (39) Total financial expenses (3,152) (2,428) Net financial income (loss) (640) (2,194) For the six month period ended June 30, 2021, the foreign exchange gains realized by the Company amounted to €2.5 million and are primarily €2.4 million related to the HSBC bank account denominated in U.S. dollars. Interest costs for the six month period ended June 30, 2021 are mainly related to the EIB loan for an amount of €2.9 million which breaks down as follows: • variable interests based on royalties to be paid on future sales for an amount of €2.0 million; • fixed interest for a total amount of €889 thousand. See Note 12.1 Conditional advances, bank loan and loan from public authorities.

Segment reporting

Segment reporting	6 Months Ended
	Jun. 30, 2021
Disclosure Of Segment Reporting [Abstract]
Segment reporting	Segment reporting In accordance with IFRS 8 – Operating Segments , reporting by operating segment is derived from the internal organization of the Company’s activities; it reflects management’s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company’s Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. Revenues for the first half of 2021, as in 2020, are mainly generated by the recharging of shared costs related to the organization of external research, in respect of development assistance provided by the Company to its partners under license agreements (see Note 15 Revenues and other income).

Loss per share

Loss per share	6 Months Ended
	Jun. 30, 2021
Disclosure Of Earnings Per Share [Abstract]
Loss per share	Loss per share For the six month period ended June 30, 2021 2020 Net loss for the period (in thousands of euros) (30,420) (20,579) Weighted average number of shares 34,619,072 22,608,408 Basic loss per share (in euros) (0.88) (0.91) Diluted loss per share (in euros) (0.88) (0.91)

Commitments

Commitments	6 Months Ended
	Jun. 30, 2021
Disclosure Of Commitments [Abstract]
Commitments	Commitments Obligations under the loan agreement with the EIB In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than €35.0 million. As the variable rate of these royalties is not linked to the performance of the stock market but to the performance of the Company, exposure to market and interest rate risk is considered low. Any subsidiary whose gross revenues, total assets or EBITDA represent at least 5% of consolidated gross revenues, total assets or EBITDA is required to guarantee EIB borrowings. Subject to certain thresholds and exceptions, the financing agreement does not permit the Company, without the prior consent of the EIB, to dispose of assets outside the ordinary course of its business, to make acquisitions or other external growth transactions, to increase debt, to grant guarantees over assets or to pay dividends. In the event of prepayment, the Company would be required to pay a cancellation fee, calculated as a percentage of the prepaid amount, which percentage decreases over time, and certain other amounts. In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan. Obligations under the terms of the rental agreements part of the IFRS 16 exemptions The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow: • One short term lease for an office by Nanobiotix Corp., of which the annual rent is €140 thousand; and • Leases related to low-value assets for Nanobiotix S.A.’s printers, of which the annual rent is around €10 thousand. Obligations related to the MD Anderson agreement In January 2019, the Company and MD Anderson announced a large-scale research collaboration. The collaboration will support multiple phase I/II clinical trials involving around 340 patients with NBTXR3 for use in treating several cancer types – including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11 million for the clinical trials contemplated by the agreement during the course of the collaboration on the basis of patients enrolled during the relevant period. As of June 30, 2021, $2 million have already been invoiced and paid since the beginning of the collaboration. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA. The amount will be determined based on the number of patients enrolled in these clinical trials as of the date of FDA registration. This number increases every year and varies between $2.2 million (if it had been payable in 2020) and $16.4 million (if payable in 2030). Obligations related to the termination of the PharmaEngine agreement In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012.

Related parties

Related parties	6 Months Ended
	Jun. 30, 2021
Disclosure Of Related Party [Abstract]
Related parties	Related parties Key management personnel compensation The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown: For the six month period ended June 30, (in thousands of euros) 2021 2020 Salaries, wages and benefits 610 687 Share-based payments 743 859 Supervisory Board’s fees 245 35 Total compensation to related parties 1,598 1,581 The methods used to measure share-based payments are presented in Note 17 Share-based payments.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2021
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	Subsequent events EIB loan In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of €40 million, divided in three tranches. The first tranche, with a nominal value of €16 million, was received in October 2018 and the second tranche, with a nominal value of €14 million, was received in March 2019. The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the third tranche of the EIB loan.

Consolidated principles and m_2

Consolidated principles and methods (Policies)	6 Months Ended
	Jun. 30, 2021
Significant Accounting Policies [Abstract]
General principles and statement of compliance and basis of presentation	General principles The interim condensed consolidated financial statements as of June 30, 2021 and for the six month period ended June 30, 2021 were prepared under the supervision of the management of the Company and were approved by the Executive Board and reviewed by the Supervisory Board on September 8, 2021. All amounts in the interim condensed consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items. The preparation of the interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. See Note 3.2 Use of judgement, estimates and assumptions. The summarized interim consolidated financial statements of the Company have been prepared in compliance with IAS 34 – “Interim Financial Reporting”. As they are interim condensed financial statements, they do not contain all information required for the consolidated annual financial statements and should therefore be read in conjunction with the consolidated financial statements of the Company for the financial year ended December 31, 2020 as described below. The interim condensed consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company’s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning multiple years. With cash and cash equivalents of €102.3 million as of June 30, 2021, the Company believes it has sufficient resources to continue operating for at least twelve months following the interim condensed consolidated financial statements’ publication. Seasonality of the Company’s activities According to IAS 34 – Interim Financial Reporting, an entity whose business is highly seasonal should present financial information for the twelve months up to the end of the interim period and additional comparative information for the prior twelve-month period in the interim condensed financial statements in order to provide a better understanding and comparison of its interim financial statements. As mentioned in Note 15 Revenues and other income, as most of the income from the Company is generated by ongoing contracts that primarily depend on performance obligations not correlated to seasonal trends, it is considered that the Company activities are not seasonal. Therefore, the following interim condensed financial statements and corresponding notes will not include comparative information other than that mentioned in IAS 34-20. Statement of compliance and basis of presentation The interim condensed consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (“IAS”) as issued by the International Accounting Standards Board (“IASB”) as well as interpretations issued by the IFRS Interpretations Committee (“IFRS-IC”) and the Standard Interpretations Committee (the “SIC”), which application is mandatory as of June 30, 2021. The interim condensed consolidated financial statements are also compliant with IFRS as adopted by the European Union. The accounting principles used to prepare the interim condensed consolidated financial statements for the six month period ended June 30, 2021 are identical to those used for the year ended December 31, 2020 except for the standards listed below that required adoption in 2021. Application of New or Amended Standards and Interpretations The Company adopted the following standards, amendments and interpretations whose application was mandatory for periods beginning on or after January 1, 2021: Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2 Flexibility measures relating to the accounting consequences of amendments to contracts following the reform of reference rates and hedge accounting criteria Amendment to IFRS 16 Amendments for COVID-19 related to rent concessions The application of these standards and these amendments had no impact on the interim consolidated condensed financial statements of the Company. Early application of New or Amended Standards and Interpretations The Company elected not to early adopt the new standards, amendments and interpretations, which application was not yet mandatory for the six month period ended June 30, 2021. IFRS 17 Insurance contracts and related amendments Amendment to IAS 1 Classification of liabilities as current and non-current Disclosure of significant accounting policies Update of Practice Statement 2 "Making materiality” Amendment to IAS 37 Onerous Contracts - Cost of Performing a Contract Amendment to IFRS 3 Conceptual Framework Amendment to IAS 8 Definition of an accounting estimate Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use The expected impact of these standards on the consolidated financial statements is not significant.
Basis of consolidation	3.1 BASIS OF CONSOLIDATION Consolidated entities As of June 30, 2021, the consolidation perimeter is identical to that of December 31, 2020 as Nanobiotix S.A. has five wholly owned subsidiaries: • Nanobiotix Corp., incorporated in the State of Delaware in September 2014 and located in the USA, • Nanobiotix Germany GmbH, created in October 2017 and located in Germany, • Nanobiotix Spain S.L.U., created in December 2017 and located in Spain, • Curadigm SAS, created on July 3, 2019 and located in France, and • Curadigm Corp., created on January 7, 2020 and located in the USA. Accordingly, the interim condensed consolidated financial statements as of June 30, 2021 include the operations of each of these subsidiaries, to the extent applicable, from the date of their incorporation. Foreign currency transactions The unaudited condensed consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar-to-euro exchange rate used in the interim condensed consolidated financial statements to convert the Group transactions denominated in US dollars were $1.1884 as of June 30, 2021 and an average of $1.2053 for the six month period ended June 30, 2021 (source: Banque de France) compared with $1.1198 and $1.1015 as of and for the six month period ended June 30, 2020, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.
Use of judgement, estimates and assumptions	3.2. USE OF JUDGEMENT, ESTIMATES AND ASSUMPTIONS The preparation of interim condensed consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. A sensitivity analysis may be presented if the results differ materially based on the application of different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. Measurement of share-based payments The Company measures the fair value of stock options (OSA), founders’ warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (e.g., vesting terms) and market data (e.g., expected share volatility) (See Note 17 Share-based payments). Deferred tax assets Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company’s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes. The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carry forwards in the statements of consolidated financial position. Clinical trials accruals Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision is recognized accordingly. (See Note 13.1 Trade and other payables for information regarding the clinical trial accruals as of June 30, 2021 and December 31, 2020). Revenue recognition In order to determine the amount and timing of revenue under the contracts with PharmaEngine and LianBio, the Company is required to use significant judgments, mainly with respect to determining the timing of satisfaction of services provided to PharmaEngine and LianBio (see Note 15 Revenues and other income below for additional detail regarding the revenue recognition related to the new agreement with LianBio). Fair value of financial instruments The fair value measurement of the loan granted by European Investment Bank (‘‘EIB’’) requires the Company to assess the amount of additional interest (‘‘royalties’’, as defined by the royalty agreement with EIB) that will be due according to the loan agreement. The royalties will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company’s consolidated annual sales turnover generated during a period of six years (“the royalty period”) commencing on January 1, 2021. For purposes of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market.
Trade receivables	TRADE RECEIVABLES Trade receivables relate mainly to invoices issued to PharmaEngine in connection with the charging-back of shared external clinical research organization costs under the Company’s license and collaboration agreement with PharmaEngine. As of June 30, 2021, trade receivables have been settled following the termination of the collaboration contract between Nanobiotix and PharmaEngine. (See Note 4 Significant transactions for more detail on the license and collaboration agreement).
Revenues and other income	Application of IFRS 15 to the license and collaboration agreement with PharmaEngine The application of IFRS 15 to the license and partnership agreement entered into in 2012 between the Company and PharmaEngine is presented in section 4.1.6.15 of the Company's universal reference document filed with the Autorité des marchés financiers ("AMF") on April 7, 2021 and in the Note 15 of the Consolidated financial statements as of and for the year ended December 31, 2021 included in the Form 20-F, as amended, filed to the Securities and Exchange Commission ("SEC) the same day. In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions. Application of IFRS 15 to the license and collaboration agreement with LianBio Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15 as the license, development services and product revenues are revenues of the Company. We identified the separate performance obligations of the contract under IFRS 15. The partnership includes the following obligations to LianBio: • an exclusive license, under the Company's intellectual property, to develop and market the licensed products, • the right to actively participate in global Phase III registration trials to obtain marketing approval in China, • if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals, • if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial, and • the requirement to purchase products under license to the Company. The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct. As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone. LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases. Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products. In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20 million and may receive up to $220 million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts. No revenue is to be recognized when such a right is granted. The upfront payment and milestone payment are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products. The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined. Grants Since its creation, the Company has received, because of its innovative approach to nanomedicine, certain grants and subsidies from the French State or French public authorities. These grants and subsidies are intended to finance its general or specified activities. Grants are recognized as income as the related expenses are incurred, irrespective of whether they are actually received. Research tax credit The research tax credit ("CIR") is granted to companies by the French government to encourage them to conduct technical and scientific research. Companies that can prove that they have incurred expenses that meet the required criteria (research expenses located in France or, since January 1, 2005, in the European Community or in another country that is a party to the Agreement on the European Economic Area and that has entered into a tax treaty with France containing an administrative assistance clause) are entitled to a tax credit which, in principle, can be offset against the corporate income tax due for the fiscal year in which the expenses were incurred and for the three

General information, statemen_2

General information, statement of compliance and basis of presentation (Tables)	6 Months Ended
	Jun. 30, 2021
General Information, Statement of Compliance and Basis of Presentation [Abstract]
Disclosure of New or Amended Standards and Interpretations	The Company adopted the following standards, amendments and interpretations whose application was mandatory for periods beginning on or after January 1, 2021: Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 Interest Rate Benchmark Reform – Phase 2 Flexibility measures relating to the accounting consequences of amendments to contracts following the reform of reference rates and hedge accounting criteria Amendment to IFRS 16 Amendments for COVID-19 related to rent concessions
Disclosure of New or Amended Standards and Interpretations Not Yet Adopted	IFRS 17 Insurance contracts and related amendments Amendment to IAS 1 Classification of liabilities as current and non-current Disclosure of significant accounting policies Update of Practice Statement 2 "Making materiality” Amendment to IAS 37 Onerous Contracts - Cost of Performing a Contract Amendment to IFRS 3 Conceptual Framework Amendment to IAS 8 Definition of an accounting estimate Amendments to IAS 16 Property, Plant and Equipment: Proceeds before Intended Use

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2021
Intangible assets other than goodwill [abstract]
Disclosure of reconciliation of changes in intangible assets	The change in intangible assets breaks down as follows: (in thousands of euros) As of December 31, 2020 Increases Decreases Transfer As of June 30, 2021 Patents 65 — — — 65 Software 651 4 — — 656 Intangible assets in progress — — — — — Gross book value of intangible assets 717 4 — — 721 Patents (65) — — — (65) Software (630) (14) — — (644) Accumulated depreciation of intangible assets (1) (695) (14) — — (709) Net book value of intangible assets 21 (10) — — 12 (1) Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses

Property, plant and equipment (

Property, plant and equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	The change in property, plant and equipment is as follows: (in thousands of euros) As of December 31, 2020 Increases Decreases Other movements & transfer. Currency As of June 30, 2021 Fixtures, fittings and installations 3,313 — — — — 3,313 Right of use – Buildings 7,171 19 — — — 7,190 Technical equipment 2,061 5 — 1 — 2,067 Office and IT equipment 988 41 (1) — 2 1,029 Transport equipment 31 — — — 1 32 Right of use – Transport equipment 65 — — — 1 66 Tangible assets in progress 1 — — (1) — 1 Gross book value of tangible assets 13,630 65 (1) — 4 13,698 Fixtures, fittings and installations (1,320) (160) — — — (1,481) Right of use – Buildings (1,739) (457) — — — (2,196) Technical equipment (1,466) (93) — — — (1,559) Office and IT equipment (783) (67) 1 — (1) (850) Transport equipment (31) — — — (1) (32) Right of use – Transport equipment (36) (10) — — (1) (46) Accumulated depreciation of tangible assets (1) (5,374) (787) 1 — (2) (6,163) Net book value of tangible assets 8,256 (722) (1) — 1 7,535

Non-current financial assets (T

Non-current financial assets (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of financial assets [abstract]
Disclosure of changes in non-current financial assets	The change in non-current financial assets breaks down as follows: (in thousands of euros) Liquidity contract - Cash account (1) Other long- Security Total Net book value as of December 31, 2019 131 — 399 529 Additions — — 9 9 Decreases (27) — (5) (31) Currency translation adjustments — — (2) (2) Net book value as of December 31, 2020 105 — 401 505 Additions — — — — Decreases (16) — — (16) Reclassifications — — 8 8 Currency translation adjustments — — 1 1 Net book value as of June 30, 2021 88 — 410 498 (1) See Note 10.2 Treasury shares

Trade receivables and other c_2

Trade receivables and other current assets (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of break down of trade receivables	As of (in thousands of euros) June 30, 2021 December 31, 2020 Trade receivables — 62 Trade receivables — 62
Disclosure of break down of other current assets	Other current assets break down as follows: As of (in thousands of euros) June 30, 2021 December 31, 2020 Research tax credit receivable 3,154 1,927 VAT receivable 1,129 971 Prepaid expenses 7,246 2,217 Other receivables 2,004 920 Other current assets 13,534 6,035
Disclosure of changes in research tax credit receivables	The change in research tax credit receivables breaks down as follows: (in thousands of euros) Receivable as of December 31, 2020 1,927 2021 research tax credit – Nanobiotix S.A. (1) 1,227 Receivable as of June 30, 2021 3,154 (1) See Note 15 Revenues and other income.

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Summary of cash and cash equivalents	Cash and cash equivalent break down as follows: As of (in thousands of euros) June 30, 2021 December 31, 2020 Cash and bank accounts 102,336 119,151 Net cash and cash equivalents 102,336 119,151

Share Capital (Tables)

Share Capital (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]
Disclosure of detail of share capital transactions	Detail of share capital transactions (in thousands or number of shares) Nature of transaction Share Capital Premiums related to share capital Number of shares December 31, 2020 1,033 255,735 34,432,122 March 31, 2021 Capital increase AGA 2018-1 1 (1) 24,500 March 31, 2021 Capital increase AGA 2019-1 11 (11) 369,250 May 31, 2021 Subscription of 2021 warrants — 43 — June 30, 2021 Other movements — 16 — June 30, 2021 1,045 255,782 34,825,872

Provisions (Tables)

Provisions (Tables)	6 Months Ended
	Jun. 30, 2021
Provisions [abstract]
Disclosure of changes in provisions	Details of provisions (in thousands of euros) As of December 31, 2020 Increases Decreases (1) As of June 30, 2021 Lump-sum retirement benefits 414 42 — 457 Non-current provisions 414 42 — 457 Provisions for disputes 40 390 — 430 Provision for charges — — — — Current provisions 40 390 — 430 Total provisions 454 432 — 887
Disclosure of commitments for retirement benefits	Commitments for retirement benefits As of (in thousands of euros) June 30, 2021 December 31, 2020 Provision as of beginning of period 414 331 Cost of services 42 76 Discounting costs 1 3 Expense for the period 43 79 Actuarial gains or losses recognized in other comprehensive income — 4 Provision as of the end of period 457 414
Disclosure of assumptions used to measure retirement benefits	The assumptions used to measure lump-sum retirement benefits are as follows: Measurement date June 30, 2021 December 31, 2020 Retirement assumptions Executive: Age 66 Non-Executive: Age 64 Executive: Age 66 Non-Executive: Age 64 Social security contribution rate 44 % 44 % Discount rate 0.33 % 0.33 % Mortality tables Regulatory table Regulatory table Salary increase rate (including inflation) Executive: 3% Non-Executive: 2.5% Executive: 3% Non-Executive: 2.5% Staff turnover Constant average rate of 5.86% Constant average rate of 5.86% Duration 17 years 17 years

Financial liabilities (Tables)

Financial liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of financial liabilities [abstract]
Disclosure of financial liabilities	Details of financial liabilities As of (in thousands of euros) June 30, 2021 December 31, 2020 Lease liabilities – Short term 714 1,197 Repayable advances OSEO/Bpifrance loan – Short term 500 500 PGE* 208 141 EIB loan – Short term 5,308 3,033 Total current financial liabilities 6,730 4,872 Lease liabilities – Long term 4,851 4,991 Repayable OSEO/Bpifrance loan advances – Long term 2,768 2,975 PGE* 9,927 9,922 EIB loan – Long term 26,441 26,218 Total non-current financial liabilities 43,988 44,107 Total financial liabilities 50,718 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Detail of financial instruments included in the statements of financial position and impact on income As of June 30, 2021 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 498 88 410 498 Trade receivables — — — — Cash and cash equivalents 102,336 — 102,336 102,336 Total assets 102,834 88 102,747 102,834 Financial liabilities Non-current financial liabilities 43,988 — 43,988 43,988 Current financial liabilities 6,730 — 6,730 6,730 Trade payables and other payables 8,813 — 8,813 8,813 Total liabilities 59,531 — 59,531 59,531 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.
Disclosure of detailed information about borrowings	Conditional advances, interest-free loans from government and public authorities (in thousands of euros) Bpifrance advance Interest-free Bpifrance loan Curadigm Bpifrance advance EIB loan Total As of December 31, 2020 2,216 974 285 29,251 32,727 Impact of discounting and accretion 9 11 8 4 31 Accumulated fixed interest expense accrual 16 — — 889 906 Accumulated variable interest expense accrual — — — 1,955 1,955 Repayment — (250) — (350) (600) As of June 30, 2021 2,241 735 292 31,749 35,018 Bank loans (in thousands of euros) HSBC Bpifrance “PGE” Total As of December 31, 2020 5,020 5,044 10,064 Impact of discounting and accretion 22 42 64 Accumulated fixed interest accrual (3) 11 8 As of June 30, 2021 5,039 5,096 10,136
Disclosure of reconciliation of changes in lease liabilities	The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the six month period ended June 30, 2021: (in thousands of euros) Lease liabilities As of December 31, 2020 6,189 New lease contracts 22 Impact of discounting of the new lease contracts (3) Fixed interest expense 152 Repayment of lease (796) As of June 30, 2021 5,564
Disclosure of maturity analysis for advances loans and lease liabilities	The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows: As of June 30, 2021 (in thousands of euros) Less than 1 year Between 1 and Between 3 and More than 5 years Total Bpifrance — 800 1,608 — 2,408 Interest-free Bpifrance loan 500 250 — — 750 Curadigm interest-free Bpifrance advance — 125 200 25 350 HSBC “PGE” (1) 40 2,572 2,545 — 5,157 Bpifrance “PGE” (1) 168 2,320 2,620 327 5,435 EIB fixed rate loan 5,308 31,328 — — 36,637 Lease liabilities 988 2,314 2,309 821 6,432 Total 7,004 39,710 9,282 1,173 57,169

Trade payables and other curr_2

Trade payables and other current liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Subclassifications of assets, liabilities and equities [abstract]
Summary of trade and other payables	Details of trade and other payables As of (in thousands of euros) June 30, 2021 December 31, 2020 Accrued expenses - clinical trials 1,572 1,532 Other trade payables 7,241 5,574 Total trade and other payables 8,813 7,106
Summary of other current liabilities	OTHER CURRENT LIABILITIES As of (in thousands of euros) June 30, 2021 December 31, 2020 Tax liabilities 305 283 Payroll tax and other payroll liabilities 4,807 6,248 Other payables 398 491 Other current liabilities 5,510 7,022
Summary of deferred income and contract liabilities	DEFERRED REVENUES AND CONTRACT LIABILITIES As of (in thousands of euros) June 30, 2021 December 31, 2020 Deferred revenues and contract liabilities 16,555 — Deferred revenues and contract liabilities 16,555 —

Financial instruments include_2

Financial instruments included in the statement of financial position and impact on income (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure of detailed information about financial instruments [abstract]
Details of non-current financial assets	Detail of financial instruments included in the statements of financial position and impact on income As of June 30, 2021 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 498 88 410 498 Trade receivables — — — — Cash and cash equivalents 102,336 — 102,336 102,336 Total assets 102,834 88 102,747 102,834 Financial liabilities Non-current financial liabilities 43,988 — 43,988 43,988 Current financial liabilities 6,730 — 6,730 6,730 Trade payables and other payables 8,813 — 8,813 8,813 Total liabilities 59,531 — 59,531 59,531 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.
Details of financial liabilities	Details of financial liabilities As of (in thousands of euros) June 30, 2021 December 31, 2020 Lease liabilities – Short term 714 1,197 Repayable advances OSEO/Bpifrance loan – Short term 500 500 PGE* 208 141 EIB loan – Short term 5,308 3,033 Total current financial liabilities 6,730 4,872 Lease liabilities – Long term 4,851 4,991 Repayable OSEO/Bpifrance loan advances – Long term 2,768 2,975 PGE* 9,927 9,922 EIB loan – Long term 26,441 26,218 Total non-current financial liabilities 43,988 44,107 Total financial liabilities 50,718 48,979 (*)”PGE”or in French “Prêts garantis par l’Etat” are state-guaranteed loans Detail of financial instruments included in the statements of financial position and impact on income As of June 30, 2021 (in thousands of euros) Book value on the statement of financial position Financial assets carried at fair value through profit or loss Assets and liabilities carried at amortized cost Fair value (1) Non-current financial assets Non-current financial assets 498 88 410 498 Trade receivables — — — — Cash and cash equivalents 102,336 — 102,336 102,336 Total assets 102,834 88 102,747 102,834 Financial liabilities Non-current financial liabilities 43,988 — 43,988 43,988 Current financial liabilities 6,730 — 6,730 6,730 Trade payables and other payables 8,813 — 8,813 8,813 Total liabilities 59,531 — 59,531 59,531 (1) The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable “level 3” inputs, in the IFRS 13 classification for fair value.

Revenues and other income (Tabl

Revenues and other income (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue [abstract]
Schedule of revenues and other income	The following table summarizes the Company’s revenues and other income per category for the six month period ended June 30, 2021 and 2020: For the six month period ended June 30, (in thousands of euros) 2021 2020 Services 5 37 Other sales 5 — Total revenues 10 37 Research tax credit 1,227 888 Subsidies 62 494 Other 20 28 Total other income 1,309 1,411 Total revenues and other income 1,319 1,448

Operating expenses (Tables)

Operating expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Analysis of income and expense [abstract]
Summary of Research and Development Expense	RESEARCH AND DEVELOPMENT EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Purchases, sub-contracting and other expenses (9,386) (7,096) Payroll costs (including share-based payments) (5,105) (5,397) Depreciation, amortization and provision expenses (1) (1,015) (583) Total research and development expenses (15,506) (13,077) (1) see Note 16.4 Depreciation, amortization and provision expenses
Disclosure of Selling, General and Administrative Expenses	SELLING, GENERAL AND ADMINISTRATIVE EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Purchases, fees and other expenses (5,152) (2,955) Payroll costs (including share-based payments) (4,848) (3,641) Depreciation, amortization and provision expenses (1) (176) (159) Total SG&A expenses (10,176) (6,755) (1) see Note 16.4 Depreciation, amortization and provision expenses
Summary of Payroll Costs	PAYROLL COSTS For the six month period ended June 30, (in thousands of euros) 2021 2020 Wages and salaries (5,939) (5,658) Payroll taxes (2,574) (1,799) Share-based payments (1,398) (1,542) Retirement benefit obligations (42) (38) Total payroll costs (9,953) (9,038) Average headcount 93 104 End-of-period headcount 98 98
Disclosure of Depreciation, Amortization and Provision Expenses	Depreciation, amortization and provision expenses by function are detailed as follows: For the six month period ended June 30, 2021 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (23) (2) (25) Amortization expense of tangible assets (602) (174) (776) Provision for charges (390) — (390) Total depreciation, amortization and provision expenses (1,015) (176) (1,191) For the six month period ended June 30, 2020 (in thousands of euros) R&D SG&A Total Amortization expense of intangible assets (73) (44) (117) Amortization expense of tangible assets (623) (167) (789) Reversal of provision for disputes 112 52 164 Total depreciation, amortization and provision expenses (583) (159) (742)
Disclosure Of Other Operating Income (Expense)	OTHER OPERATING INCOME AND EXPENSES For the six month period ended June 30, (in thousands of euros) 2021 2020 Contract termination indemnities (PharmaEngine) 5,414 — Total Other operating income and expenses 5,414 —

Share-based payments (Tables)

Share-based payments (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payments Arrangements [Abstract]
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding	The number of options and warrants outstanding on June 30, 2021 and their main characteristics, are detailed below: Founders’ warrants BSPCE 2012-2 BSPCE 08-2013 BSPCE 09-2014 BSPCE 2015-1 BSPCE 2015-3 Date of the shareholders' meeting 4-May-12 28-Jun-13 18-Jun-14 18-Jun-14 18-Jun-14 Date of grant by the Executive Board 18-dec-12 28-Aug-13 16-Sep-14 10-Feb-15 10-Jun-15 Total number of BSPCEs authorized 500,000 500,000 450,000 450,000 450,000 Total number of BSPCEs granted 100,000 50,000 97,200 71,650 53,050 Total number of shares to which the BSPCE were likely to give right on the date of their grant 100,000 50,000 97,200 71,650 53,050 the number of which that may be subscribed by corporate officers: — — 21,000 24,000 — the number that can be subscribed by Laurent LEVY — — 21,000 24,000 — Number of beneficiaries who are not corporate officers 2 1 30 13 42 Starting date for the exercise of the BSPCE 12/18/12 08/28/13 09/16/15 02/10/2016 06/10/2016 BSPCE expiry date 12/18/22 08/28/23 09/16/24 02/10/2025 06/10/2025 BSPCE exercise price €6.63 €5.92 €18.68 €18.57 €20.28 Number of shares subscribed as of June 30, 2021 — — — — — Total number of BSPCEs lapsed or cancelled as of June 30, 2021 — — 11,050 3,200 22,350 Total number of BSPCEs outstanding as of June 30, 2021 100,000 50,000 86,150 68,450 30,700 Total number of shares available for subscription as of June 30, 2021 100,000 50,000 86,150 68,450 30,700 Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of the related BSPCEs are met) 100,000 50,000 86,150 68,450 30,700 BSPCE 2016 Ordinary BSPCE 2016 Performance BSPCE 2017 Ordinary BSPCE “2017” Date of the shareholders' meeting 25-Jun-15 25-Jun-15 23-Jun-16 23-Jun-16 Date of grant by the Executive Board 2-Feb-16 2-Feb-16 7-Jan-17 7-Jan-17 Total number of BSPCEs authorized 450,000 450,000 450,000 450,000 Total number of BSPCEs granted 126,400 129,250 117,650 80,000 Total number of shares to which the BSPCE were likely to give right on the date of their grant 126,400 129,250 117,650 80,000 the number of which that may be subscribed by corporate officers: 23,500 23,500 26,400 32,000 the number of which that may be subscribed by Laurent LEVY 23,500 23,500 26,400 32,000 Number of beneficiaries who are not corporate officers 43 50 42 3 Starting date for the exercise of the BSPCE 02/02/2017 02/02/2016 01/08/2018 01/07/2017 BSPCE expiry date 02/02/2026 02/02/2026 01/07/2027 01/07/2027 BSPCE exercise price €14.46 €14.46 €15.93 €15.93 Number of shares subscribed as of June 30, 2021 333 — — — Total number of BSPCEs lapsed or cancelled as of June 30, 2021 25,150 28,426 16,800 — Total number of BSPCEs outstanding as of June 30, 2021 100,917 100,824 100,850 80,000 Total number of shares available for subscription as of June 30, 2021 100,917 38,544 100,850 80,000 Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSPCEs (assuming that all the conditions for the exercise of said BSPCEs are met) 100,917 100,824 100,850 80,000 Warrants BSA 04-12 BSA 2013 BSA 2014 BSA 2015-1 BSA 2015-2 (a) BSA 2016-2 BSA 2017 Date of the shareholders’ meeting 4-May-12 4-May-12 18-Jun-14 18-Jun-14 18-Jun-14 23-Jun-16 23-Jun-16 Date of grant by the Executive Board 4-May-12 10-Apr-13 16-Sep-14 10-Feb-15 25-Jun-15 3-Nov-16 7-Jan-17 Maximum number of BSAs authorized 200,000 200,000 100,000 100,000 100,000 100,000 100,000 Total number of BSAs granted 52,500 10,000 14,000 26,000 64,000 8,000 18,000 Number of shares to which the BSA were likely to give right on the date of their grant 52,500 10,000 14,000 26,000 64,000 8,000 18,000 including the total number of shares that may subscribed by the corporate officers of the Company 22,500 — 8,000 15,000 — — 13,280 Relevant officers: Anne-Marie GRAFFIN 5,000 3,820 Enno SPILLNER 3,000 3,820 Alain HERRERA 4,000 5,000 2,820 Gary PHILLIPS Christophe DOUAT (observer) 22,500 4,000 2,000 2,820 Number of beneficiaries who are not corporate officers 1 1 1 2 1 2 1 Starting date for the exercise of the BSA 10/23/2013 04/30/2014 09/16/2014 02/10/2015 06/25/2015 11/03/2016 01/07/2017 BSA expiry date (6) 05/04/2022 04/10/2023 09/16/2024 02/10/2025 06/25/2025 11/03/2021 01/07/2022 BSA issue price €0.60 €2.50 €4.87 €4.87 €5.00 €2.03 €2.26 Exercise price per BSA €6.00 €6.37 €17.67 €17.67 €19.54 €15.01 €15.76 Number of shares subscribed as of June 30, 2021 22,500 — — — — — — Total number of forfeited or cancelled BSAs as of June 30, 2021 — 4,000 4,000 5,000 — — — Total number of BSAs outstanding as of June 30, 2021 30,000 6,000 10,000 21,000 64,000 8,000 18,000 Total number of shares available for subscription as of June 30, 2021 (considering the conditions of exercise of the BSAs) 30,000 6,000 — — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met) 30,000 6,000 10,000 21,000 64,000 8,000 18,000 BSA 2018 BSA 2018-1 BSA 2018-2 BSA 2019-1 BSA 2020 BSA 2021 (a) BSA 2021 (b) Date of the shareholders’ meeting 14-Jun-17 14-Jun-17 23-May-18 23-May-18 11-Apr-19 30-Nov-20 30-Nov-20 Date of grant by the Executive Board 6-Mar-18 6-Mar-18 27-Jul-18 29-Mar-19 17-Mar-20 20-Apr-21 20-Apr-21 Maximum number of BSAs authorized 116,000 116,000 140,000 140,000 500,000 650,000 650,000 Total number of BSAs granted 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Number of shares to which the BSA were likely to give right on the date of their grant 18,000 10,000 5,820 18,000 18,000 48,103 30,000 including the total number of shares that may subscribed by the corporate officers of the Company 12,700 — — 12,700 14,024 33,672 — Relevant officers: Anne-Marie GRAFFIN 2,900 2,900 3,843 8,500 Enno SPILLNER 4,000 4,000 3,829 8,200 Alain HERRERA 2,900 2,900 3,195 9,227 Gary PHILLIPS Christophe DOUAT (observer) 2,900 2,900 3,157 7,745 Number of beneficiaries who are not corporate officers 1 1 1 1 1 1 1 Starting date for the exercise of the BSA 03/06/2018 03/06/2018 07/27/18 03/29/19 03/17/20 04/20/21 04/20/21 BSA expiry date (6) 03/06/2023 03/06/2023 07/27/28 03/29/29 03/17/30 04/20/31 04/20/31 BSA issue price €1.62 €1.62 €2.36 €1.15 €0.29 €2.95 €0.68 Exercise price per BSA €13.55 €13.55 €16.10 €11.66 €6.59 €13.47 €13.64 Number of shares subscribed as of June 30, 2021 — — — — — — — Total number of forfeited or cancelled BSAs as of June 30, 2021 — — — — — — — Total number of BSAs outstanding as of June 30, 2021 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Total number of shares available for subscription as of June 30, 2021 (considering the conditions of exercise of the BSAs) — — — — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding BSAs (assuming that all the conditions for the exercise of said BSAs are met) 18,000 10,000 5,820 18,000 18,000 48,103 30,000 Free shares AGA 2018-1 AGA 2018-2 AGA 2019-1 AGA 2020 AGA 2021 Date of the shareholders’ meeting 14-Jun-17 23-May-18 23-May-18 11-Apr-19 30-Nov-20 Date of grant by the Executive Board 6-Mar-18 27-Jul-18 29-Mar-19 11-Mar-20 20-Apr-21 Total number of AGAs authorized 526,800 648,000 648,000 650,000 850,000 Total number of AGAs granted 396,250 6,000 438,250 50,000 362,515 Total number of shares to which the AGAs were likely to give right on the date of their grant 396,250 6,000 438,250 50,000 362,515 including the number that can be subscribed by corporate officers: 77,500 — 150,000 50,000 270,000 the number that can be subscribed by Laurent LEVY 77,500 — 150,000 — 180,000 the number that can be subscribed by Anne-Juliette HERMANT — — — 50,000 90,000 Number of beneficiaries who are not corporate officers 78 1 80 — 79 Date of acquisition (end of the acquisition period) (1) 07/27/20 (2) 03/11/22 04/20/23 Number of shares subscribed as of June 30, 2021 340,583 6,000 369,250 — — Total number of AGAs lapsed or cancelled as of June 30, 2021 55,667 — 69,000 — 2 Total number of AGAs outstanding as of June 30, 2021 — — — 50,000 362,513 Total number of shares that may be subscribed — — — 50,000 362,513 Duration of the holding period (1) 1 year (2) 1 year 1 year (1) The AGA2018-1 granted to French tax residents were definitely acquired on March 6, 2020 were subject to a one-year holding period ending on March 6, 2021. The AGA2018-1 granted to foreign tax residents were definitely acquired on March 6, 2021 and will not be subject to any holding period. (2) The AGA2019-1 granted to French tax residents were definitely acquired on March 29, 2021 and will then be subject to a one-year holding period ending on March 29, 2022. The AGA2019-1 granted to foreign tax residents will be definitely acquired on March 29, 2022 and will not be subject to any holding period. BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of June 30, 2021 717,891 304,923 1,670,524 412,513 3,105,851
Disclosure of number and weighted average remaining contractual life of outstanding share options	Stock options OSA 2016-1 Performance OSA 2016-2 OSA 2017 Ordinary OSA 2018 OSA 2019-1 OSA 2019 LLY Date of the shareholders’ meeting 25-Jun-15 23-Jun-16 23-Jun-16 14-Jun-17 23-May-18 11-Apr-19 Date of grant by the Executive Board 02-Feb-16 03-Nov-16 07-Jan-17 6-Mar-18 29-Mar-19 24-Oct-19 Total number of OSAs authorized 450,000 450,000 450,000 526,800 648,000 650,000 Total number of OSAs granted 6,400 4,000 3,500 62,000 37,500 500,000 Total number of shares to which the OSAs were likely to give right on the date of their grant 6,400 4,000 3,500 62,000 37,500 500,000 including the number that may be subscribed or purchased by corporate officers: — — — — — 500,000 the number that can be subscribed by Laurent LEVY 500,000 the number that can be subscribed by Anne-Juliette HERMANT the number that can be subscribed by Bart VAN RHIJN Number of beneficiaries who are not corporate officers 2 1 2 5 12 — Starting date for the exercise of the OSA 02/02/2017 11/03/2017 01/08/2018 03/07/2019 03/30/2021 10/24/2019 OSA expiry date 02/02/2026 11/03/2026 01/07/2027 03/06/2028 03/29/2029 10/24/2029 Exercise price per OSA €13.05 €14.26 €14.97 €12.87 €11.08 €6.41 Number of shares subscribed as of June 30, 2021 — — — — — — Total number of lapsed or cancelled OSAs as of June 30, 2021 6,000 — 3,000 10,000 8,750 — Total number of OSAs outstanding as of June 30, 2021 400 4,000 500 52,000 28,750 500,000 Maximum number of shares available for subscription as of June 30, 2021 (given the vesting conditions of the OSAs) 120 4,000 500 52,000 19,165 — Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met) 400 4,000 500 52,000 28,750 500,000 OSA 2020 OSA 2021-04 Ordinary OSA 2021-04 Performance OSA 2021-06 Performance OSA 2021-06 Ordinary Date of the shareholders’ meeting 11-Apr-19 30-Nov-20 30-Nov-20 30-Nov-20 28-Apr-21 Date of grant by the Executive Board 11-Mar-20 20-Apr-21 20-Apr-21 21-Jun-21 21-Jun-21 Total number of OSAs authorized 650,000 850,000 1,000,000 1,000,000 850,000 Total number of OSAs granted 407,972 143,200 428,000 60,000 60,000 Total number of shares to which the OSAs were likely to give right on the date of their grant 407,972 143,200 428,000 60,000 60,000 including the number that may be subscribed or purchased by corporate officers: 180,000 — 240,000 60,000 60,000 the number that can be subscribed by Laurent LEVY 120,000 180,000 the number that can be subscribed by Anne-Juliette HERMANT 60,000 60,000 the number that can be subscribed by Bart VAN RHIJN 60,000 60,000 Number of beneficiaries who are not corporate officers 104 13 14 — — Starting date for the exercise of the OSA 03/11/2021 04/20/22 04/20/22 06/21/22 06/21/22 OSA expiry date 03/11/2030 04/20/31 04/20/31 06/21/31 06/21/31 Exercise price per OSA €6.25 €13.74 €13.74 €12.99 €12.99 Number of shares subscribed as of June 30, 2021 — — — — — Total number of lapsed or cancelled OSAs as of June 30, 2021 14,298 — — — — Total number of OSAs outstanding as of June 30, 2021 393,674 143,200 428,000 60,000 60,000 Maximum number of shares available for subscription as of June 30, 2021 (given the vesting conditions of the OSAs) 172,147 — — — — Maximum total number of shares that may be subscribed for upon exercise of all outstanding OSAs (assuming that all the conditions for the exercise of said OSAs are met) 393,674 143,200 428,000 60,000 60,000 BSPCE BSA OSA AGA Total Total number of shares underlying grants outstanding as of June 30, 2021 717,891 304,923 1,670,524 412,513 3,105,851
Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period	The fair value of 2012-1 founders’ warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. The data used for the estimation and measurement of new awards and ongoing awards are detailed below: BSPCE Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) BSPCE 2012-1 5.26 5.26 41 % 3.49 0.20 % 0.00 % 307 — — BSPCE 2012-2 6.65 6.63 44.3% - 47.6% 5 - 7.30 0.84% - 1.22% 0.00 % 288 — — BSPCE 04-2013 6.30 6.30 56 % 5 0.90 % 0.00 % 167 — — BSPCE 08-2013 6.30 5.92 256 % 7 0.90 % 0.00 % 152 — — BSPCE 09-2014 18.68 18.68 58 % 5.5/6/6.5 0.64 % 0.00 % 932 — — BSPCE 2015-2 18.57 18.57 58% - 62% - 61% 5.5/6/6.5 0.39 % 0.00 % 650 — — BSPCE 2015-3 20.28 20.28 61% - 62% - 61% 5.5/6/6.5 0.56 % 0.00 % 483 — — BSPCE 2016 Ordinary 14.46 14.46 59% - 62% - 60% 5.5/6/6.5 0.32 % 0.00 % 1,080 — — BSPCE 2016 Performance 14.46 14.46 59 % 5 0.19 % 0.00 % 1,212 5 63 BSPCE 2017 Ordinary 15.93 15.93 58% - 61% - 59% 5.5/6/6.5 0.23 % 0.00 % 1,000 — 8 BSPCE 2017 Performance 15.93 15.93 59 % 5 0.11 % 0.00 % 622 — — BSPCE 2017 15.93 15.93 59 % 5 0.11 % 0.00 % 627 — — BSPCE 2017 Project 15.93 15.93 59 % 5 0.11 % 0.00 % 94 — — Total BSPCE n.a. n.a. n.a. n.a. n.a. n.a. n.a. 5 71 BSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) BSA 04-2012 6.00 6.00 49 % 10 0.96 % 0.00 % 183 — — BSA 2013 6.30 6.37 156 % 6 0.90 % 0.00 % 1 — — BSA 2014 18.68 17.67 57 % 5 0.41 % 0.00 % — — — BSA 2015-1 17.67 17.67 58 % 5 0.26% - 0.27% 0.00 % 63 — — BSA 2015-2 (a) 17.67 19.54 58%-58%-57%-58% 5/5.1/5.3/5.4 0.39 % 0.00 % 16 — — BSA 2015-2 (b) 19.54 19.54 58% - 60% 4.6 – 9.6 0.25% - 0.91% 0.00 % 284 — — BSA 2016o 13.74 13.74 57 % 2.4 0.00 % 0.00 % 37 — — BSA 2016p 13.74 13.74 57 % 2.4 0.00 % 0.00 % 143 — — BSA 2016-2 15.01 15.01 57 % 2.4 0.00 % 0.00 % — — — BSA 2017 15.76 15.76 33 % 2.4 0.00 % 0.00 % — — — BSA 2018 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % 2 — — BSA 2018-1 13.55 13.55 38 % 4.8 0.7% - 0.1% 0.00 % — — — BSA 2018-2 16.10 16.10 38 % 4.8 0.7% - 0.1% 0.00 % 1 — — BSA 2019-1 11.66 11.66 37 % 9.8/9.9 0.16% - 0.50% 0.00 % 24 — — BSA 2020 13.03 6.59 38 % 10 -0.13%/ 0.00 % 19 — 19 BSA 2021 (a) 13.47 13.47 39.10 % 10 0.27 % 0.00 % 44 44 — BSA 2021 (b) n.a. 13.64 n.a. 10 n.a. 0.00 % — — — Total BSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 44 19 AGA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) AGA 2018-1 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 4,951 16 224 AGA 2018-2 12.87 0.00 n.a. n.a. 0.00 % 0.00 % 75 — 19 AGA 2019-1 10.90 0.00 n.a. n.a. 0.19% / 0.141% 0.00 % 4,776 422 960 AGA 2020 5.90 0.00 n.a. n.a. -0.74%/ 0.00 % 287 71 43 AGA 2021 13.60 0.00 n.a. n.a. -0.63% / -0.59% 0.00 % 4,869 473 — Total AGA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 983 1,246 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2021 5 44 367 983 1,398 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2020 71 19 205 1,246 1,542
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period	OSA Share price (in euros) Exercise price (in euros) Volatility Maturity (in years) Risk-free rate Yield Value of initial plan (in thousands of euros) Expense for the first half of 2021 (in thousands of euros) Expense for the first half of 2020 (in thousands of euros) OSA 2016 Ordinary 13.05 13.05 59% - 62% - 60% 5.5 / 6 /6.5 0.32 % 0.00 % 117 — — OSA 2016 Performance 13.05 13.05 59 % 5 0.19 % 0.00 % 69 — — OSA 2016-2 14.26 14.26 58% - 62% - 59% 5.5 / 6 /6.5 0.04 % 0.00 % 27 — — OSA 2017 Ordinary 15.93 14.97 58% - 61% - 59% 5.5 / 6 /6.5 0.23 % 0.00 % 31 — — OSA 2017 Performance 15.93 14.97 59 % 5 0.11 % 0.00 % 35 — — OSA 2018 12.87 12.87 35 % 5.5 / 6 /6.5 0.00 % 0.00 % 252 — 6 OSA 2019-1 11.08 11.08 38.1% / 37.4% 6 /6.5 0.103% / 0.149% 0.00 % 140 13 27 OSA 2019-2 6.41 6.41 37 % 10 0.40 % 0.00 % 252 — — OSA 2020 6.25 6.25 38 % 10 0.31 % 0.00 % 939 225 172 OSA 2021-04 O 13.60 13.74 38.9% - 37.8% - 38.3 % 5.5 / 6 / 6.5 -0.38% / -0.33% / -0.28% 0.00 % 684 80 — OSA 2021-04 P 13.60 13.74 39.10 % 10 0.03 % 0.00 % 1,816 39 — OSA 2021-06 O 12.20 12.99 39.2% - 37.8% - 38.1% 5.5 / 6 / 6.5 -0.35% / -0.30% / -0.26% 0.00 % 246 4 — OSA 2021-06 P 12.20 12.99 39.10 % 10 0.13 % 0.00 % 212 5 — Total OSA n.a. n.a. n.a. n.a. n.a. n.a. n.a. 367 205 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2021 5 44 367 983 1,398 (in thousands of euros) BSPCE BSA OSA AGA Total Expense for the year ended June 30, 2020 71 19 205 1,246 1,542

Net financial income (loss) (Ta

Net financial income (loss) (Tables)	6 Months Ended
	Jun. 30, 2021
Net Financial Income (Loss) [Abstract]
Summary of Net Financial Income (Loss)	For the six month period ended June 30, (in thousands of euros) 2021 2020 Income from cash and cash equivalents — — Foreign exchange gains 2,511 177 Other financial income — 56 Total financial income 2,511 234 Interest cost (2,960) (2,219) IFRS 16 related interests (152) (169) Foreign exchange losses (39) (39) Total financial expenses (3,152) (2,428) Net financial income (loss) (640) (2,194)

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Share	For the six month period ended June 30, 2021 2020 Net loss for the period (in thousands of euros) (30,420) (20,579) Weighted average number of shares 34,619,072 22,608,408 Basic loss per share (in euros) (0.88) (0.91) Diluted loss per share (in euros) (0.88) (0.91)

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Related Party [Abstract]
Summary of Key Management Personnel Compensation	The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown: For the six month period ended June 30, (in thousands of euros) 2021 2020 Salaries, wages and benefits 610 687 Share-based payments 743 859 Supervisory Board’s fees 245 35 Total compensation to related parties 1,598 1,581

Company information - Overview

Company information - Overview of the Company (Details)	Jun. 30, 2021platformpatent_family
Disclosure Of Information Related To The Company [Abstract]
Number of patent families owned | patent_family	30
Number of nanotechnology platforms owned | platform	3

Company information - Key Event

Company information - Key Events of the Six Month Period Ended June 30, 2021 (Details) € in Millions, $ in Millions	Jun. 15, 2021USD ($)	May 31, 2021study	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)
Disclosure Of Information Related To The Company [Line Items]
Royalties agreement, period						6 years	6 years
Termination of PharmaEngine collaboration agreement, NBTXR3
Disclosure Of Information Related To The Company [Line Items]
Contractual commitments, payment			$ 2.5		$ 4	$ 6.5	€ 5.4
Contractual commitments, milestone payment upon receipt of clinical study reports			1
Contractual commitments, milestone payment upon second regulatory approval			$ 5
Royalties agreement, period			10 years
Termination of PharmaEngine collaboration agreement, NBTXR3 | Maximum
Disclosure Of Information Related To The Company [Line Items]
Onerous contracts provision			$ 12.5
LianBio, NBTXR3
Disclosure Of Information Related To The Company [Line Items]
Number of global registrational studies supported | study		5
Collaboration agreement, upfront payment received	$ 20			$ 20
LianBio, NBTXR3 | Maximum
Disclosure Of Information Related To The Company [Line Items]
Collaboration agreement, potential development and commercial milestones payments				$ 220	$ 220	$ 220

General information, statemen_3

General information, statement of compliance and basis of presentation (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
General Information, Statement of Compliance and Basis of Presentation [Abstract]
Cash and cash equivalents	€ 102,336	€ 119,151	€ 26,590	€ 35,094

Consolidated principles and m_3

Consolidated principles and methods (Details)	6 Months Ended
	Jun. 30, 2021subsidiary	Jun. 30, 2020
Significant Accounting Policies [Abstract]
Number of subsidiaries	5
Closing foreign exchange rate	1.1884	1.1198
Average foreign exchange rate	1.2053	1.1015
Royalties agreement, period	6 years

Significant transactions (Detai

Significant transactions (Details) € in Thousands, $ in Millions	Jun. 15, 2021USD ($)	May 31, 2021study	Mar. 31, 2021USD ($)	Jul. 31, 2018EUR (€)	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)patient	Jun. 30, 2021EUR (€)patient	Jun. 30, 2021EUR (€)	Dec. 31, 2020EUR (€)	Jan. 31, 2019USD ($)
Disclosure of transactions between related parties [line items]
Royalties agreement, period							6 years	6 years
Prepaid expenses | €									€ 7,246	€ 2,217
Termination of PharmaEngine collaboration agreement, NBTXR3
Disclosure of transactions between related parties [line items]
Contractual commitments, payment			$ 2.5			$ 4	$ 6.5	€ 5,400
Contractual commitments, milestone payment upon receipt of clinical study reports			1
Contractual commitments, milestone payment upon second regulatory approval			$ 5
Royalties agreement, period			10 years
LianBio, NBTXR3
Disclosure of transactions between related parties [line items]
Number of global registrational studies supported | study		5
Collaboration agreement, upfront payment received	$ 20				$ 20
MD Anderson Cancer Center, NBTXR3
Disclosure of transactions between related parties [line items]
Number of patients in clinical trial | patient							340	340
Contractual commitments, payment											$ 11
Prepaid expenses | €									€ 1,300	€ 1,600
EIB loan
Disclosure of transactions between related parties [line items]
Royalties agreement, period				6 years
Maximum | LianBio, NBTXR3
Disclosure of transactions between related parties [line items]
Collaboration agreement, potential development and commercial milestones payments					$ 220	$ 220	$ 220
Maximum | EIB loan
Disclosure of transactions between related parties [line items]
Notional amount | €				€ 40,000

Intangible assets - Schedule of

Intangible assets - Schedule of Intangible Assets (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	€ 21
Increases	(10)
Decreases	0
Transfer	0
Intangible assets at end of period	12
Gross book value of intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	717
Increases	4
Decreases	0
Transfer	0
Intangible assets at end of period	721
Gross book value of intangible assets | Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	65
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	65
Gross book value of intangible assets | Software
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	651
Increases	4
Decreases	0
Transfer	0
Intangible assets at end of period	656
Gross book value of intangible assets | Intangible assets in progress
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	0
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	0
Accumulated depreciation of intangible assets
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(695)
Increases	(14)
Decreases	0
Transfer	0
Intangible assets at end of period	(709)
Accumulated depreciation of intangible assets | Patents
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(65)
Increases	0
Decreases	0
Transfer	0
Intangible assets at end of period	(65)
Accumulated depreciation of intangible assets | Software
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(630)
Increases	(14)
Decreases	0
Transfer	0
Intangible assets at end of period	€ (644)

Intangible assets - Additional

Intangible assets - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Intangible assets other than goodwill [abstract]
Impairment loss recognised in profit or loss, intangible assets other than goodwill	€ 0

Property, plant and equipment -

Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	€ 8,256
Increases	(722)
Decreases	(1)
Other movements & transfer.	0
Currency translation	1
Property, plant and equipment at end of period	7,535
Gross book value of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	13,630
Increases	65
Decreases	(1)
Other movements & transfer.	0
Currency translation	4
Property, plant and equipment at end of period	13,698
Gross book value of tangible assets | Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	3,313
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	3,313
Gross book value of tangible assets | Right of use – Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	7,171
Increases	19
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	7,190
Gross book value of tangible assets | Technical equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	2,061
Increases	5
Decreases	0
Other movements & transfer.	1
Currency translation	0
Property, plant and equipment at end of period	2,067
Gross book value of tangible assets | Office and IT equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	988
Increases	41
Decreases	(1)
Other movements & transfer.	0
Currency translation	2
Property, plant and equipment at end of period	1,029
Gross book value of tangible assets | Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	31
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	1
Property, plant and equipment at end of period	32
Gross book value of tangible assets | Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	65
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	1
Property, plant and equipment at end of period	66
Gross book value of tangible assets | Tangible assets in progress
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	1
Increases	0
Decreases	0
Other movements & transfer.	(1)
Currency translation	0
Property, plant and equipment at end of period	1
Accumulated depreciation of tangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(5,374)
Increases	(787)
Decreases	1
Other movements & transfer.	0
Currency translation	(2)
Property, plant and equipment at end of period	(6,163)
Accumulated depreciation of tangible assets | Fixtures, fittings and installations
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,320)
Increases	(160)
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(1,481)
Accumulated depreciation of tangible assets | Right of use – Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,739)
Increases	(457)
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(2,196)
Accumulated depreciation of tangible assets | Technical equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(1,466)
Increases	(93)
Decreases	0
Other movements & transfer.	0
Currency translation	0
Property, plant and equipment at end of period	(1,559)
Accumulated depreciation of tangible assets | Office and IT equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(783)
Increases	(67)
Decreases	1
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	(850)
Accumulated depreciation of tangible assets | Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(31)
Increases	0
Decreases	0
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	(32)
Accumulated depreciation of tangible assets | Right of use – Transport equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning of period	(36)
Increases	(10)
Decreases	0
Other movements & transfer.	0
Currency translation	(1)
Property, plant and equipment at end of period	€ (46)

Non-current financial assets -

Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	€ 505	€ 529
Additions	0	9
Decreases	(16)	(31)
Currency translation adjustments	1	(2)
Reclassifications	8
Non-current financial assets at end of period	498	505
Liquidity contract - Cash account | Financial assets at fair value, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	105	131
Additions	0	0
Decreases	(16)	(27)
Currency translation adjustments	0	0
Reclassifications	0
Non-current financial assets at end of period	88	105
Other long- term investments pledged as collateral | Financial assets at amortised cost, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	0	0
Additions	0	0
Decreases	0	0
Currency translation adjustments	0	0
Reclassifications	0
Non-current financial assets at end of period	0	0
Security deposits paid | Financial assets at amortised cost, class
Disclosure of financial assets [line items]
Non-current financial assets at beginning of period	401	399
Additions	0	9
Decreases	0	(5)
Currency translation adjustments	1	(2)
Reclassifications	8
Non-current financial assets at end of period	€ 410	€ 401

Trade receivables and other c_3

Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables	€ 0	€ 62

Trade receivables and other c_4

Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Research tax credit receivable	€ 3,154	€ 1,927
VAT receivable	1,129	971
Prepaid expenses	7,246	2,217
Other receivables	2,004	920
Other current assets	€ 13,534	€ 6,035

Trade receivables and other c_5

Trade receivables and other current assets - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	€ 7,246	€ 2,217
Current advances to suppliers	1,400	805
Research agreement
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	7,200
ICON Plc
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	4,400
MD Anderson Cancer Center, NBTXR3
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Prepaid expenses	€ 1,300	€ 1,600

Trade receivables and other c_6

Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of Trade Receivables and Other Current Assets [Line Items]
Research tax credit receivable at beginning of period	€ 1,927
Research tax credit receivable at end of period	3,154
2021 Tax Year
Disclosure of Trade Receivables and Other Current Assets [Line Items]
2021 research tax credit – Nanobiotix S.A.	€ 1,227

Cash and cash equivalents - Sum

Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Subclassifications of assets, liabilities and equities [abstract]
Cash and bank accounts	€ 102,336	€ 119,151
Net cash and cash equivalents	€ 102,336	€ 119,151	€ 26,590	€ 35,094

Share Capital - Detail of Share

Share Capital - Detail of Share Capital Transactions (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of classes of share capital [line items]
Equity at beginning of period	€ 70,468	€ (1,909)
Capital increase	0	0
Subscription of 2021 warrants	43	5
Other movements	0
Equity at end of period	41,431	(22,194)
Share Capital
Disclosure of classes of share capital [line items]
Equity at beginning of period	€ 1,033	€ 672
Number of shares outstanding at beginning of period (in shares)	34,432,122	22,415,039
Capital increase	€ 12	€ 9
Capital increase (in shares)	393,750	316,083
Equity at end of period	€ 1,045	€ 682
Number of shares outstanding at end of period (in shares)	34,825,872	22,731,122
Premiums related to share capital
Disclosure of classes of share capital [line items]
Equity at beginning of period	€ 255,735	€ 153,139
Capital increase	(12)
Subscription of 2021 warrants	43	5
Other movements	16
Equity at end of period	255,782	€ 151,968
AGA 2018-1 | Share Capital
Disclosure of classes of share capital [line items]
Capital increase	€ 1
Capital increase (in shares)	24,500
AGA 2018-1 | Premiums related to share capital
Disclosure of classes of share capital [line items]
Capital increase	€ (1)
AGA 2019-1 | Share Capital
Disclosure of classes of share capital [line items]
Capital increase	€ 11
Capital increase (in shares)	369,250
AGA 2019-1 | Premiums related to share capital
Disclosure of classes of share capital [line items]
Capital increase	€ (11)

Share Capital - Capital Issued

Share Capital - Capital Issued (Details) - EUR (€) € / shares in Units, € in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure of classes of share capital [line items]
Total shareholders’ equity	€ 41,431	€ 70,468	€ (22,194)	€ (1,909)
Par value per share (euro per share)	€ 0.03
Share Capital
Disclosure of classes of share capital [line items]
Total shareholders’ equity	€ 1,045	€ 1,033	€ 682	€ 672
Number of shares outstanding (in shares)	34,825,872	34,432,122	22,731,122	22,415,039

Share Capital - Treasury Shares

Share Capital - Treasury Shares (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Treasury shares	€ 212	€ 196
Treasury shares
Disclosure of classes of share capital [line items]
Number of shares outstanding (in shares)	15,053

Share Capital - Founder's Warra

Share Capital - Founder's Warrants, Warrants, Stock Options and Free Shares (Details)	Jun. 30, 2021plan_type
Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]
Number of share-based payment arrangement plans type	4

Share Capital - Warrant Plans (

Share Capital - Warrant Plans (Details)	Jun. 30, 2021shares€ / shares	Apr. 20, 2021sharespatient€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share) | € / shares	€ 0.03
BSA 2021 (a)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		48,103
Exercise price (in euros per share) | € / shares		€ 13.47
Number of awards subscribed (in shares)	0
BSA 2021 (a) | Supervisory Board
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		48,103
Number of ordinary share subscribed per each BSA (in shares)		1
Par value per share (euro per share) | € / shares		€ 0.03
Exercise price (in euros per share) | € / shares		€ 13.47
Number of awards subscribed (in shares)	14,431
Maximum term of other equity instruments granted for share-based payment arrangement		10 years
Vesting requirements, minimum attendance		75.00%
Vesting requirements, attendance period		12 months
Vesting requirements, recommended dose determination, minimum number of patients | patient		2
Vesting requirements, recommended dose determination, total number of patients | patient		3
BSA 2021 (a) in replacement of BSA 2016 | Supervisory Board
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		18,103
BSA 2021 (b)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		30,000
Exercise price (in euros per share) | € / shares		€ 13.64
Number of awards subscribed (in shares)	0
BSA 2021 (b) | External consultant
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares)		30,000
Number of ordinary share subscribed per each BSA (in shares)		1
Par value per share (euro per share) | € / shares		€ 0.03
Exercise price (in euros per share) | € / shares		€ 13.64
Number of awards subscribed (in shares)	0
Maximum term of other equity instruments granted for share-based payment arrangement		10 years

Share Capital - Stock Option Pl

Share Capital - Stock Option Plans (Details)	Jun. 21, 2021sharespatient€ / shares	Apr. 20, 2021shares€ / shares	Nov. 30, 2020€ / shares	Jun. 30, 2021€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share)				€ 0.03
OSA 2021-04 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares		143,200
Exercise price (in euros per share)		€ 13.74
OSA 2021-04 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares		428,000
Exercise price (in euros per share)		€ 13.74
OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum term of options granted for share-based payment arrangement			10 years
OSA | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			10.00%
Share price milestone, Euronext Paris			€ 24
OSA | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			10.00%
Share price milestone, Euronext Paris			€ 30
OSA | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			40.00%
Share price milestone, Euronext Paris			€ 40
OSA | Tranche four
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage			40.00%
Share price milestone, Euronext Paris			€ 60
OSA | From first year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			10.00%
OSA | From second year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			30.00%
OSA | From third year of grant date
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, maximum percentage exercised			60.00%
OSA 2021-06 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares	60,000
Exercise price (in euros per share)	€ 12.99
OSA 2021-06 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares	60,000
Exercise price (in euros per share)	€ 12.99
Executive Board and Employees | OSA 2021-04
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares		571,200
Number of ordinary share subscribed per each OSA | shares		1
Par value per share (euro per share)		€ 0.03
Exercise price (in euros per share)		€ 13.74
Maximum term of options granted for share-based payment arrangement		10 years
Executive Board and Employees | OSA 2021-04 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees | OSA 2021-04 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees | OSA 2021-04 | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements for share-based payment arrangement, vesting percentage		33.33%
Executive Board and Employees | OSA 2021-04 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares		143,200
Executive Board and Employees | OSA 2021-04 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares		428,000
Bart VAN RHIJN | OSA 2021-06 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares	60,000
Bart VAN RHIJN | OSA 2021-06 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares	60,000
Bart VAN RHIJN | OSA 2021-06
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total number of share options granted (in shares) | shares	120,000
Number of ordinary share subscribed per each OSA | shares	1
Par value per share (euro per share)	€ 0.03
Exercise price (in euros per share)	€ 12.99
Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn | OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting requirements, recommended dose determination, minimum number of patients | patient	2
Vesting requirements, recommended dose determination, total number of patients | patient	3

Share Capital - Free Share Plan

Share Capital - Free Share Plans (Details)	Apr. 20, 2021sharespatient€ / shares	Jun. 30, 2021€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Par value per share (euro per share) | € / shares		€ 0.03
AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) | shares	362,515
Vesting requirements, holding period	1 year
Executive Board and Employees | AGA 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued (in shares) | shares	362,515
Par value per share (euro per share) | € / shares	€ 0.03
Vesting requirements, holding period	1 year
Vesting requirements, acquisition period	2 years
Vesting requirements, recommended dose determination, minimum number of patients | patient	2
Vesting requirements, recommended dose determination, total number of patients | patient	3

Provisions - Disclosure of Chan

Provisions - Disclosure of Changes in Provisions (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of other provisions [table]
Other provisions at beginning of period	€ 454
Increases	432
Decreases	0
Other provisions at end of period	887
Non-current provisions
Disclosure of other provisions [table]
Other provisions at beginning of period	414
Increases	42
Decreases	0
Other provisions at end of period	457
Lump-sum retirement benefits
Disclosure of other provisions [table]
Other provisions at beginning of period	414
Increases	42
Decreases	0
Other provisions at end of period	457
Current provisions
Disclosure of other provisions [table]
Other provisions at beginning of period	40
Increases	390
Decreases	0
Other provisions at end of period	430
Provisions for disputes
Disclosure of other provisions [table]
Other provisions at beginning of period	40
Increases	390
Decreases	0
Other provisions at end of period	430
Provision for charges
Disclosure of other provisions [table]
Other provisions at beginning of period	0
Increases	0
Decreases	0
Other provisions at end of period	€ 0

Provisions - Additional Informa

Provisions - Additional Information (Details) € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Disclosure of other provisions [table]
Additional provisions, other provisions	€ 432
Provisions for disputes
Disclosure of other provisions [table]
Additional provisions, other provisions	€ 390

Provisions - Disclosure of Comm

Provisions - Disclosure of Commitments for Retirement Benefits (Details) - EUR (€) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Provisions [abstract]
Provision as of beginning of period	€ 414	€ 331	€ 331
Cost of services	42	€ 38	76
Discounting costs	1		3
Expense for the period	43		79
Actuarial gains or losses recognized in other comprehensive income	0		4
Provision as of the end of period	€ 457		€ 414

Provisions - Disclosure of Assu

Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [table]
Social security contribution rate	44.00%	44.00%
Discount rate	0.33%	0.33%
Staff turnover	0.0586%	0.0586%
Duration	17 years	17 years
Management
Disclosure of defined benefit plans [table]
Retirement assumptions	66 years	66 years
Non-management
Disclosure of defined benefit plans [table]
Retirement assumptions	64 years	64 years
Executive
Disclosure of defined benefit plans [table]
Salary increase rate (including inflation)	3.00%	3.00%
Non-executive
Disclosure of defined benefit plans [table]
Salary increase rate (including inflation)	0.025%	0.025%

Financial liabilities - Summary

Financial liabilities - Summary of Changes in Financial Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	€ 6,730	€ 4,872
Non-current financial liabilities	43,988	44,107
Total financial liabilities	50,718	48,979
Lease liabilities
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	714	1,197
Non-current financial liabilities	4,851	4,991
Conditional advances
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	500	500
Non-current financial liabilities	2,768	2,975
PGE | Long-term borrowings
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	208	141
Non-current financial liabilities	9,927	9,922
EIB loan | Long-term borrowings
Disclosure Of Changes In Financial Liabilities [Line Items]
Current financial liabilities	5,308	3,033
Non-current financial liabilities	€ 26,441	€ 26,218

Financial liabilities - Additio

Financial liabilities - Additional Information (Details) € in Thousands	Jul. 10, 2020EUR (€)quarterly_instalment	Jun. 22, 2020EUR (€)quarterly_instalment	Jul. 31, 2020	Mar. 31, 2019EUR (€)	Oct. 31, 2018EUR (€)	Jul. 31, 2018EUR (€)tranche	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2018EUR (€)tranche	Jun. 05, 2020EUR (€)
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Proceeds from borrowings							€ 0	€ 5,350
Royalties agreement, period							6 years
EIB loan
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of tranches | tranche						3			3
Proceeds from borrowings				€ 14,000	€ 16,000
Borrowing, deferment period to request funds			12 months
Royalties agreement, period						6 years
Borrowings							€ 36,600
EIB loan | Fixed interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable							6,600
Interest payable							2,900
EIB loan | Variable interest rate
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Total interest payable							€ 17,200
EIB loan | Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount						€ 40,000			€ 40,000
HSBC "PGE" and Bpifrance "PGE"
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount										€ 10,000
Percentage of State-Guaranteed loan										0.90
Borrowing, maturity							5 years
HSBC “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Proceeds from borrowings		€ 5,000
Percentage of State-Guaranteed loan		0.90
Borrowing, maturity		6 years
Borrowing, initial period bearing no interest		12 months
Borrowing, subsequent period bearing interest		5 years
Borrowing, interest rate		0.31%
Borrowing, guarantee fee		0.50%
Borrowing, guarantee fee for the last three years		1.00%
Borrowing, initial period bearing no interest, extension period requested		12 months
Bpifrance “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Proceeds from borrowings	€ 5,000
Percentage of State-Guaranteed loan	0.90
Borrowing, maturity	6 years
Borrowing, initial period bearing no interest	12 months
Borrowing, subsequent period bearing interest	5 years
Borrowing, interest rate	2.25%
Borrowing, guarantee fee	1.61%
Number of quarterly instalments | quarterly_instalment	20
Banque Publique d’Investissement
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances deferment period									18 months
Advances received									€ 2,100
Bpifrance
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Advances received								350
Authorized amount to be advanced								€ 500
Tranche one | HSBC “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of quarterly instalments | quarterly_instalment		20
Tranche two | HSBC “PGE”
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of quarterly instalments | quarterly_instalment		16

Financial liabilities - Summa_2

Financial liabilities - Summary of Conditional Advances and Interest-Free Loans from Government and Public Authorities (Details) - Conditional advances and loans from Government and Public Authorities € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 32,727
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	31
Accumulated fixed interest expense accrual	906
Accumulated variable interest expense accrual	1,955
Repayment	(600)
Liabilities arising from financing activities at end of period	35,018
Bpifrance advance
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	2,216
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	9
Accumulated fixed interest expense accrual	16
Accumulated variable interest expense accrual	0
Repayment	0
Liabilities arising from financing activities at end of period	2,241
Interest-free Bpifrance loan
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	974
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	11
Accumulated fixed interest expense accrual	0
Accumulated variable interest expense accrual	0
Repayment	(250)
Liabilities arising from financing activities at end of period	735
Curadigm Bpifrance advance
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	285
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	8
Accumulated fixed interest expense accrual	0
Accumulated variable interest expense accrual	0
Repayment	0
Liabilities arising from financing activities at end of period	292
EIB loan
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	29,251
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	4
Accumulated fixed interest expense accrual	889
Accumulated variable interest expense accrual	1,955
Repayment	(350)
Liabilities arising from financing activities at end of period	€ 31,749

Financial liabilities - Summa_3

Financial liabilities - Summary of Bank Loans (Details) - Long-term borrowings € in Thousands	6 Months Ended
	Jun. 30, 2021EUR (€)
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	€ 10,064
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	64
Accumulated fixed interest accrual	8
Liabilities arising from financing activities at end of period	10,136
HSBC “PGE”
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	5,020
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	22
Accumulated fixed interest accrual	(3)
Liabilities arising from financing activities at end of period	5,039
Bpifrance “PGE”
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	5,044
Changes in liabilities arising from financing activities [abstract]
Impact of discounting and accretion	42
Accumulated fixed interest accrual	11
Liabilities arising from financing activities at end of period	€ 5,096

Financial liabilities - Summa_4

Financial liabilities - Summary of Changes in Lease Liabilities (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Fixed interest expense	€ 152	€ 169
Lease liabilities
Summary Of Conditional Advances, Banks Loans And Loans [Line Items]
Liabilities arising from financing activities at beginning of period	6,189
New lease contracts	22
Impact of discounting of the new lease contracts	(3)
Fixed interest expense	152
Repayment of lease	(796)
Liabilities arising from financing activities at end of period	€ 5,564

Financial liabilities - Summa_5

Financial liabilities - Summary of Maturity Analysis for Advances Loans and Lease Liabilities (Details) - EUR (€) € in Thousands	Jul. 10, 2020	Jun. 22, 2020	Jun. 30, 2021
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			€ 6,432
Total			57,169
Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			988
Total			7,004
Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			2,314
Total			39,710
Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			2,309
Total			9,282
More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Lease liabilities			821
Total			1,173
Bpifrance
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,408
Bpifrance | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Bpifrance | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			800
Bpifrance | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			1,608
Bpifrance | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Interest-free Bpifrance loan
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			750
Interest-free Bpifrance loan | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			500
Interest-free Bpifrance loan | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			250
Interest-free Bpifrance loan | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Interest-free Bpifrance loan | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Curadigm interest-free Bpifrance advance
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			350
Curadigm interest-free Bpifrance advance | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Curadigm interest-free Bpifrance advance | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			125
Curadigm interest-free Bpifrance advance | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			200
Curadigm interest-free Bpifrance advance | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			25
HSBC "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			5,157
Borrowing, maturity		6 years
HSBC "PGE" | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			40
HSBC "PGE" | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,572
HSBC "PGE" | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,545
HSBC "PGE" | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			5,435
Borrowing, maturity	6 years
Bpifrance "PGE" | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			168
Bpifrance "PGE" | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,320
Bpifrance "PGE" | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			2,620
Bpifrance "PGE" | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			327
EIB fixed rate loan
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			36,637
EIB fixed rate loan | Less than 1 year
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			5,308
EIB fixed rate loan | Between 1 and 3 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			31,328
EIB fixed rate loan | Between 3 and 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			0
EIB fixed rate loan | More than 5 years
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowings			€ 0
HSBC "PGE" and Bpifrance "PGE"
Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]
Borrowing, maturity			5 years
Borrowing, deferment period			1 year

Trade payables and other curr_3

Trade payables and other current liabilities - Disclosure of Trade And Other Payables (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Accrued expenses - clinical trials	€ 1,572	€ 1,532
Other trade payables	7,241	5,574
Total trade and other payables	€ 8,813	€ 7,106

Trade payables and other curr_4

Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Tax liabilities	€ 305	€ 283
Payroll tax and other payroll liabilities	4,807	6,248
Other payables	398	491
Other current liabilities	€ 5,510	€ 7,022

Trade payables and other curr_5

Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Deferred revenues and contract liabilities	€ 16,555	€ 0

Trade payables and other curr_6

Trade payables and other current liabilities - Additional Information (Details) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Deferred revenues and contract liabilities	€ 16,555	€ 0
LianBio, NBTXR3
Disclosure of Trade Payables and Other Current Liabilities [Line Items]
Deferred revenues and contract liabilities	€ 16,600

Financial instruments include_3

Financial instruments included in the statement of financial position and impact on income - Schedule of Financial Assets/Liabilities (Details) € in Thousands	Jun. 30, 2021EUR (€)
Disclosure of detailed information about financial instruments [line items]
Total financial assets	€ 102,834
Total financial assets, at fair value	102,834
Total financial liabilities	59,531
Total financial liabilities, at fair value	59,531
Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	59,531
Non-current financial liabilities
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	43,988
Total financial liabilities, at fair value	43,988
Non-current financial liabilities | Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	43,988
Current financial liabilities
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	6,730
Total financial liabilities, at fair value	6,730
Current financial liabilities | Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	6,730
Trade payables and other payables
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	8,813
Total financial liabilities, at fair value	8,813
Trade payables and other payables | Financial liabilities at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial liabilities	8,813
Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Total financial assets	88
Financial assets at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial assets	102,747
Non-current financial assets
Disclosure of detailed information about financial instruments [line items]
Total financial assets	498
Total financial assets, at fair value	498
Non-current financial assets | Financial assets carried at fair value through profit or loss
Disclosure of detailed information about financial instruments [line items]
Total financial assets	88
Non-current financial assets | Financial assets at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial assets	410
Trade receivables
Disclosure of detailed information about financial instruments [line items]
Total financial assets	0
Total financial assets, at fair value	0
Trade receivables | Financial assets at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial assets	0
Cash and cash equivalents
Disclosure of detailed information about financial instruments [line items]
Total financial assets	102,336
Total financial assets, at fair value	102,336
Cash and cash equivalents | Financial assets at amortised cost
Disclosure of detailed information about financial instruments [line items]
Total financial assets	€ 102,336

Financial instruments include_4

Financial instruments included in the statement of financial position and impact on income - Additional Information (Details) - EIB loan € in Millions	1 Months Ended	12 Months Ended	42 Months Ended
	Jul. 31, 2018EUR (€)tranche	Dec. 31, 2018EUR (€)tranche	Jun. 30, 2021tranche
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Number of tranches	3	3
Number of tranches received			2
Top of range
Disclosure Of Detailed Information About Financial Liabilities [Line Items]
Notional amount | €	€ 40	€ 40

Revenues and other income - Add

Revenues and other income - Additional Information (Details) € in Thousands, $ in Millions	Jun. 30, 2021USD ($)	Jun. 15, 2021USD ($)	May 31, 2021	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Research tax credit utilisation period					3 years
Decrease in subsidies | €						€ 432
LianBio, NBTXR3
Disclosure of disaggregation of revenue from contracts with customers [line items]
Minimum threshold to provide additional know-how to LianBio			80.00%
Collaboration agreement, upfront payment received		$ 20		$ 20
Collaboration agreement, milestones achievement, period	18 months
LianBio, NBTXR3 | Maximum
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaboration agreement, potential development and commercial milestones payments	$ 220			$ 220	$ 220

Revenues and other income - Sch

Revenues and other income - Schedule of Revenues (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	€ 10	€ 37
Research tax credit	1,227	888
Subsidies	62	494
Other	20	28
Other income	1,309	1,411
Total revenues and other income	1,319	1,448
Services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	5	37
Other sales
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenues	€ 5	€ 0

Operating expenses - Research a

Operating expenses - Research and Development Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Analysis of income and expense [abstract]
Purchases, sub-contracting and other expenses	€ (9,386)	€ (7,096)
Payroll costs (including share-based payments)	(5,105)	(5,397)
Depreciation, amortization, and provision expenses	(1,015)	(583)
Total research and development expenses	€ (15,506)	€ (13,077)

Operating expenses - Additional

Operating expenses - Additional Information (Details) € in Thousands, $ in Millions	1 Months Ended	4 Months Ended	6 Months Ended
	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)employee	Jun. 30, 2021USD ($)employee	Jun. 30, 2021EUR (€)employee	Jun. 30, 2020EUR (€)employee
Disclosure Of Operating Expenses [Line Items]
Percentage of increase in employee benefit expense			(15.00%)	(15.00%)
Increase in employee benefit expense				€ (1,100)
Number of employees | employee		98	98	98	98
Expense from share-based payment transactions with employees				€ 1,398	€ 1,542
Termination of PharmaEngine collaboration agreement, NBTXR3
Disclosure Of Operating Expenses [Line Items]
Contractual commitments, payment	$ 2.5	$ 4	$ 6.5	5,400
R&D
Disclosure Of Operating Expenses [Line Items]
Increase in purchases, sub-contracting and other expenses				€ 2,300
Number of employees | employee		70	70	70
SG&A
Disclosure Of Operating Expenses [Line Items]
Increase in purchases, fees, and other expenses				€ 2,200
Percentage of increase in employee benefit expense			33.00%	33.00%
Increase in employee benefit expense				€ 1,200
Number of employees | employee		28	28	28

Operating expenses - Selling, G

Operating expenses - Selling, General and Administrative Expenses (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Analysis of income and expense [abstract]
Purchases, fees and other expenses	€ (5,152)	€ (2,955)
Payroll costs (including share-based payments)	(4,848)	(3,641)
Depreciation, amortization and provision expenses	(176)	(159)
Total SG&A expenses	€ (10,176)	€ (6,755)

Operating expenses - Payroll Co

Operating expenses - Payroll Costs (Details) € in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021EUR (€)employee	Jun. 30, 2020EUR (€)employee	Dec. 31, 2020EUR (€)
Analysis of income and expense [abstract]
Wages and salaries	€ (5,939)	€ (5,658)
Payroll taxes	(2,574)	(1,799)
Share-based payments	(1,398)	(1,542)
Retirement benefit obligations	(42)	(38)	€ (76)
Total payroll costs	€ (9,953)	€ (9,038)
Average headcount | employee	93	104
End-of-period headcount | employee	98	98

Operating expenses - Depreciati

Operating expenses - Depreciation, Amortisation, Provision Expense (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	€ (25)	€ (117)
Amortization expense of tangible assets	(776)	(789)
Provision for charges	(390)
Reversal of provision for disputes		164
Total depreciation, amortization and provision expenses	(1,191)	(742)
R&D
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	(23)	(73)
Amortization expense of tangible assets	(602)	(623)
Provision for charges	(390)
Reversal of provision for disputes		112
Total depreciation, amortization and provision expenses	(1,015)	(583)
SG&A
Disclosure Of Operating Expenses [Line Items]
Amortization expense of intangible assets	(2)	(44)
Amortization expense of tangible assets	(174)	(167)
Provision for charges	0
Reversal of provision for disputes		52
Total depreciation, amortization and provision expenses	€ (176)	€ (159)

Operating expenses - Other Oper

Operating expenses - Other Operating Income (Expense) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Analysis of income and expense [abstract]
Contract termination indemnities (PharmaEngine)	€ 5,414	€ 0
Total Other operating income and expenses	€ 5,414	€ 0

Share-based payments - Disclosu

Share-based payments - Disclosure of Detail of Change in Founders' Warrants, Warrants, and Free Shares (Details)	Jun. 30, 2021shares	Apr. 20, 2021shares€ / shares	Mar. 17, 2020shares€ / shares	Mar. 11, 2020shares	Mar. 29, 2019shares€ / shares	Jul. 27, 2018shares€ / shares	Mar. 06, 2018shares€ / shares	Jan. 07, 2017shares€ / shares	Nov. 03, 2016shares€ / shares	Feb. 02, 2016shares€ / shares	Jun. 25, 2015shares€ / shares	Jun. 10, 2015shares€ / shares	Feb. 10, 2015shares€ / shares	Sep. 16, 2014shares€ / shares	Aug. 28, 2013shares€ / shares	Apr. 10, 2013shares€ / shares	Dec. 18, 2012shares€ / shares	May 04, 2012shares€ / shares	Jun. 30, 2021shares€ / shares
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	3,105,851																		3,105,851
BSPCE
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	717,891																		717,891
BSPCE 2012-2
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)																	500,000
Total number of awards granted (in shares)																	100,000
Total number of shares to which the awards were likely to give right (in shares)																	100,000
Exercise price (in euros per share) | € / shares																	€ 6.63
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	100,000																		100,000
Total number of awards available for subscription (in shares)	100,000																		100,000
Maximum total number of awards that may be subscribed (in shares)	100,000																		100,000
BSPCE 2012-2 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																	0
BSPCE 2012-2 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																	0
BSPCE 2012-2 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																	2
BSPCE 08-2013
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)															500,000
Total number of awards granted (in shares)															50,000
Total number of shares to which the awards were likely to give right (in shares)															50,000
Exercise price (in euros per share) | € / shares															€ 5.92
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	50,000																		50,000
Total number of awards available for subscription (in shares)	50,000																		50,000
Maximum total number of awards that may be subscribed (in shares)	50,000																		50,000
BSPCE 08-2013 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)															0
BSPCE 08-2013 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)															0
BSPCE 08-2013 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)															1
BSPCE 09-2014
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)														450,000
Total number of awards granted (in shares)														97,200
Total number of shares to which the awards were likely to give right (in shares)														97,200
Exercise price (in euros per share) | € / shares														€ 18.68
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	11,050
Total number of awards outstanding (in shares)	86,150																		86,150
Total number of awards available for subscription (in shares)	86,150																		86,150
Maximum total number of awards that may be subscribed (in shares)	86,150																		86,150
BSPCE 09-2014 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														21,000
BSPCE 09-2014 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														21,000
BSPCE 09-2014 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														30
BSPCE 2015-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)													450,000
Total number of awards granted (in shares)													71,650
Total number of shares to which the awards were likely to give right (in shares)													71,650
Exercise price (in euros per share) | € / shares													€ 18.57
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	3,200
Total number of awards outstanding (in shares)	68,450																		68,450
Total number of awards available for subscription (in shares)	68,450																		68,450
Maximum total number of awards that may be subscribed (in shares)	68,450																		68,450
BSPCE 2015-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													24,000
BSPCE 2015-1 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													24,000
BSPCE 2015-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													13
BSPCE 2015-3
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)												450,000
Total number of awards granted (in shares)												53,050
Total number of shares to which the awards were likely to give right (in shares)												53,050
Exercise price (in euros per share) | € / shares												€ 20.28
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	22,350
Total number of awards outstanding (in shares)	30,700																		30,700
Total number of awards available for subscription (in shares)	30,700																		30,700
Maximum total number of awards that may be subscribed (in shares)	30,700																		30,700
BSPCE 2015-3 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)												0
BSPCE 2015-3 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)												0
BSPCE 2015-3 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)												42
BSPCE 2016 Ordinary
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)										450,000
Total number of awards granted (in shares)										126,400
Total number of shares to which the awards were likely to give right (in shares)										126,400
Exercise price (in euros per share) | € / shares										€ 14.46
Number of awards subscribed (in shares)	333
Total number of awards lapsed, cancelled or forfeited (in shares)	25,150
Total number of awards outstanding (in shares)	100,917																		100,917
Total number of awards available for subscription (in shares)	100,917																		100,917
Maximum total number of awards that may be subscribed (in shares)	100,917																		100,917
BSPCE 2016 Ordinary | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										23,500
BSPCE 2016 Ordinary | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										23,500
BSPCE 2016 Ordinary | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										43
BSPCE 2016 Performance
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)										450,000
Total number of awards granted (in shares)										129,250
Total number of shares to which the awards were likely to give right (in shares)										129,250
Exercise price (in euros per share) | € / shares										€ 14.46
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	28,426
Total number of awards outstanding (in shares)	100,824																		100,824
Total number of awards available for subscription (in shares)	38,544																		38,544
Maximum total number of awards that may be subscribed (in shares)	100,824																		100,824
BSPCE 2016 Performance | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										23,500
BSPCE 2016 Performance | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										23,500
BSPCE 2016 Performance | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)										50
BSPCE 2017 Ordinary
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)								450,000
Total number of awards granted (in shares)								117,650
Total number of shares to which the awards were likely to give right (in shares)								117,650
Exercise price (in euros per share) | € / shares								€ 15.93
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	16,800
Total number of awards outstanding (in shares)	100,850																		100,850
Total number of awards available for subscription (in shares)	100,850																		100,850
Maximum total number of awards that may be subscribed (in shares)	100,850																		100,850
BSPCE 2017 Ordinary | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								26,400
BSPCE 2017 Ordinary | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								26,400
BSPCE 2017 Ordinary | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								42
BSPCE 2017
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)								450,000
Total number of awards granted (in shares)								80,000
Total number of shares to which the awards were likely to give right (in shares)								80,000
Exercise price (in euros per share) | € / shares								€ 15.93
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	80,000																		80,000
Total number of awards available for subscription (in shares)	80,000																		80,000
Maximum total number of awards that may be subscribed (in shares)	80,000																		80,000
BSPCE 2017 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								32,000
BSPCE 2017 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								32,000
BSPCE 2017 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								3
BSA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	304,923																		304,923
BSA 04-12
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)																		200,000
Total number of awards granted (in shares)																		52,500
Total number of shares to which the awards were likely to give right (in shares)																		52,500
Exercise price (in euros per share) | € / shares																		€ 6
Number of awards subscribed (in shares)	22,500
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	30,000																		30,000
Total number of awards available for subscription (in shares)	30,000																		30,000
Maximum total number of awards that may be subscribed (in shares)	30,000																		30,000
Grant price (in euro per share) | € / shares																		€ 0.60
BSA 04-12 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																		22,500
BSA 04-12 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																		22,500
BSA 04-12 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																		1
BSA 2013
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)																200,000
Total number of awards granted (in shares)																10,000
Total number of shares to which the awards were likely to give right (in shares)																10,000
Exercise price (in euros per share) | € / shares																€ 6.37
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	4,000
Total number of awards outstanding (in shares)	6,000																		6,000
Total number of awards available for subscription (in shares)	6,000																		6,000
Maximum total number of awards that may be subscribed (in shares)	6,000																		6,000
Grant price (in euro per share) | € / shares																€ 2.50
BSA 2013 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																0
BSA 2013 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)																1
BSA 2014
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)														100,000
Total number of awards granted (in shares)														14,000
Total number of shares to which the awards were likely to give right (in shares)														14,000
Exercise price (in euros per share) | € / shares														€ 17.67					€ 40
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	4,000
Total number of awards outstanding (in shares)	10,000																		10,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	10,000																		10,000
Grant price (in euro per share) | € / shares														€ 4.87
BSA 2014 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														8,000
BSA 2014 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														4,000
BSA 2014 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														4,000
BSA 2014 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)														1
BSA 2015-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)													100,000
Total number of awards granted (in shares)													26,000
Total number of shares to which the awards were likely to give right (in shares)													26,000
Exercise price (in euros per share) | € / shares													€ 17.67
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	5,000
Total number of awards outstanding (in shares)	21,000																		21,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	21,000																		21,000
Grant price (in euro per share) | € / shares													€ 4.87
BSA 2015-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													15,000
BSA 2015-1 | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													5,000
BSA 2015-1 | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													3,000
BSA 2015-1 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													5,000
BSA 2015-1 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													2,000
BSA 2015-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)													2
BSA 2015-2 (a)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)											100,000
Total number of awards granted (in shares)											64,000
Total number of shares to which the awards were likely to give right (in shares)											64,000
Exercise price (in euros per share) | € / shares											€ 19.54
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	64,000																		64,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	64,000																		64,000
Grant price (in euro per share) | € / shares											€ 5
BSA 2015-2 (a) | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)											0
BSA 2015-2 (a) | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)											1
BSA 2016-2
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)									100,000
Total number of awards granted (in shares)									8,000
Total number of shares to which the awards were likely to give right (in shares)									8,000
Exercise price (in euros per share) | € / shares									€ 15.01
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	8,000																		8,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	8,000																		8,000
Grant price (in euro per share) | € / shares									€ 2.03
BSA 2016-2 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)									0
BSA 2016-2 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)									2
BSA 2017
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)								100,000
Total number of awards granted (in shares)								18,000
Total number of shares to which the awards were likely to give right (in shares)								18,000
Exercise price (in euros per share) | € / shares								€ 15.76
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000																		18,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	18,000																		18,000
Grant price (in euro per share) | € / shares								€ 2.26
BSA 2017 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								13,280
BSA 2017 | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								3,820
BSA 2017 | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								3,820
BSA 2017 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								2,820
BSA 2017 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								2,820
BSA 2017 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)								1
BSA 2018
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)							116,000
Total number of awards granted (in shares)							18,000
Total number of shares to which the awards were likely to give right (in shares)							18,000
Exercise price (in euros per share) | € / shares							€ 13.55
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000																		18,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	18,000																		18,000
Grant price (in euro per share) | € / shares							€ 1.62
BSA 2018 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							12,700
BSA 2018 | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							2,900
BSA 2018 | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							4,000
BSA 2018 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							2,900
BSA 2018 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							2,900
BSA 2018 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							1
BSA 2018-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)							116,000
Total number of awards granted (in shares)							10,000
Total number of shares to which the awards were likely to give right (in shares)							10,000
Exercise price (in euros per share) | € / shares							€ 13.55
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	10,000																		10,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	10,000																		10,000
Grant price (in euro per share) | € / shares							€ 1.62
BSA 2018-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							0
BSA 2018-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							1
BSA 2018-2
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)						140,000
Total number of awards granted (in shares)						5,820
Total number of shares to which the awards were likely to give right (in shares)						5,820
Exercise price (in euros per share) | € / shares						€ 16.10
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	5,820																		5,820
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	5,820																		5,820
Grant price (in euro per share) | € / shares						€ 2.36
BSA 2018-2 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						0
BSA 2018-2 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						1
BSA 2019-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)					140,000
Total number of awards granted (in shares)					18,000
Total number of shares to which the awards were likely to give right (in shares)					18,000
Exercise price (in euros per share) | € / shares					€ 11.66
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000																		18,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	18,000																		18,000
Grant price (in euro per share) | € / shares					€ 1.15
BSA 2019-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					12,700
BSA 2019-1 | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					2,900
BSA 2019-1 | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					4,000
BSA 2019-1 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					2,900
BSA 2019-1 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					2,900
BSA 2019-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					1
BSA 2020
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)			500,000
Total number of awards granted (in shares)			18,000
Total number of shares to which the awards were likely to give right (in shares)			18,000
Exercise price (in euros per share) | € / shares			€ 6.59
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	18,000																		18,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	18,000																		18,000
Grant price (in euro per share) | € / shares			€ 0.29
BSA 2020 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			14,024
BSA 2020 | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			3,843
BSA 2020 | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			3,829
BSA 2020 | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			3,195
BSA 2020 | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			3,157
BSA 2020 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)			1
BSA 2021 (a)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)		650,000
Total number of awards granted (in shares)		48,103
Total number of shares to which the awards were likely to give right (in shares)		48,103
Exercise price (in euros per share) | € / shares		€ 13.47
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	48,103																		48,103
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	48,103																		48,103
Grant price (in euro per share) | € / shares		€ 2.95
BSA 2021 (a) | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		33,672
BSA 2021 (a) | Anne-Marie GRAFFIN
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		8,500
BSA 2021 (a) | Enno SPILLNER
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		8,200
BSA 2021 (a) | Alain HERRERA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		9,227
BSA 2021 (a) | Christophe DOUAT (observer)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		7,745
BSA 2021 (a) | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		1
BSA 2021 (b)
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)		650,000
Total number of awards granted (in shares)		30,000
Total number of shares to which the awards were likely to give right (in shares)		30,000
Exercise price (in euros per share) | € / shares		€ 13.64
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	30,000																		30,000
Total number of awards available for subscription (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	30,000																		30,000
Grant price (in euro per share) | € / shares		€ 0.68
BSA 2021 (b) | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		0
BSA 2021 (b) | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		1
AGA
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards outstanding (in shares)	412,513																		412,513
AGA 2018-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)							526,800
Total number of awards granted (in shares)							396,250
Total number of shares to which the awards were likely to give right (in shares)							396,250
Number of awards subscribed (in shares)	340,583
Total number of awards lapsed, cancelled or forfeited (in shares)	55,667
Total number of awards outstanding (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	0																		0
AGA 2018-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							77,500
AGA 2018-1 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							77,500
AGA 2018-1 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							0
AGA 2018-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)							78
AGA 2018-1 | French tax residents
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Vesting requirements, holding period							1 year
AGA 2018-2
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)						648,000
Total number of awards granted (in shares)						6,000
Total number of shares to which the awards were likely to give right (in shares)						6,000
Number of awards subscribed (in shares)	6,000
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	0																		0
Vesting requirements, holding period						1 year
AGA 2018-2 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						0
AGA 2018-2 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						0
AGA 2018-2 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						0
AGA 2018-2 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)						1
AGA 2019-1
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)					648,000
Total number of awards granted (in shares)					438,250
Total number of shares to which the awards were likely to give right (in shares)					438,250
Number of awards subscribed (in shares)	369,250
Total number of awards lapsed, cancelled or forfeited (in shares)	69,000
Total number of awards outstanding (in shares)	0																		0
Maximum total number of awards that may be subscribed (in shares)	0																		0
AGA 2019-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					150,000
AGA 2019-1 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					150,000
AGA 2019-1 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					0
AGA 2019-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)					80
AGA 2019-1 | French tax residents
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Vesting requirements, holding period					1 year
AGA 2020
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)				650,000
Total number of awards granted (in shares)				50,000
Total number of shares to which the awards were likely to give right (in shares)				50,000
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	0
Total number of awards outstanding (in shares)	50,000																		50,000
Maximum total number of awards that may be subscribed (in shares)	50,000																		50,000
Vesting requirements, holding period				1 year
AGA 2020 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)				50,000
AGA 2020 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)				0
AGA 2020 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)				50,000
AGA 2020 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)				0
AGA 2021
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of awards authorised (in shares)		850,000
Total number of awards granted (in shares)		362,515
Total number of shares to which the awards were likely to give right (in shares)		362,515
Number of awards subscribed (in shares)	0
Total number of awards lapsed, cancelled or forfeited (in shares)	2
Total number of awards outstanding (in shares)	362,513																		362,513
Maximum total number of awards that may be subscribed (in shares)	362,513																		362,513
Vesting requirements, holding period		1 year
AGA 2021 | Corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		270,000
AGA 2021 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		180,000
AGA 2021 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		90,000
AGA 2021 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding
Total number of shares to which the awards were likely to give right (in shares)		79

Share-based payments - Disclo_2

Share-based payments - Disclosure of Changes In Share Options (Details)	Jun. 30, 2021shares	Jun. 21, 2021shares€ / shares	Apr. 20, 2021shares€ / shares	Mar. 11, 2020shares€ / shares	Oct. 24, 2019shares€ / shares	Mar. 29, 2019shares€ / shares	Mar. 06, 2018shares€ / shares	Jan. 07, 2017shares€ / shares	Nov. 03, 2016shares€ / shares	Feb. 02, 2016shares€ / shares
OSA
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options outstanding (in shares)	1,670,524
OSA 2016-1 Performance
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)										450,000
Total number of share options granted (in shares)										6,400
Total number of shares to which the share options were likely to give right (in shares)										6,400
Exercise price (in euros per share) | € / shares										€ 13.05
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	6,000
Total number of share options outstanding (in shares)	400
Maximum number of shares available for subscription (in shares)	120
Maximum total number of shares that may be subscribed (in shares)	400
OSA 2016-1 Performance | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)										0
OSA 2016-1 Performance | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)										2
OSA 2016-2
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)									450,000
Total number of share options granted (in shares)									4,000
Total number of shares to which the share options were likely to give right (in shares)									4,000
Exercise price (in euros per share) | € / shares									€ 14.26
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	4,000
Maximum number of shares available for subscription (in shares)	4,000
Maximum total number of shares that may be subscribed (in shares)	4,000
OSA 2016-2 | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)									0
OSA 2016-2 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)									1
OSA 2017 Ordinary
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)								450,000
Total number of share options granted (in shares)								3,500
Total number of shares to which the share options were likely to give right (in shares)								3,500
Exercise price (in euros per share) | € / shares								€ 14.97
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	3,000
Total number of share options outstanding (in shares)	500
Maximum number of shares available for subscription (in shares)	500
Maximum total number of shares that may be subscribed (in shares)	500
OSA 2017 Ordinary | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)								0
OSA 2017 Ordinary | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)								2
OSA 2018
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)							526,800
Total number of share options granted (in shares)							62,000
Total number of shares to which the share options were likely to give right (in shares)							62,000
Exercise price (in euros per share) | € / shares							€ 12.87
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	10,000
Total number of share options outstanding (in shares)	52,000
Maximum number of shares available for subscription (in shares)	52,000
Maximum total number of shares that may be subscribed (in shares)	52,000
OSA 2018 | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)							0
OSA 2018 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)							5
OSA 2019-1
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)						648,000
Total number of share options granted (in shares)						37,500
Total number of shares to which the share options were likely to give right (in shares)						37,500
Exercise price (in euros per share) | € / shares						€ 11.08
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	8,750
Total number of share options outstanding (in shares)	28,750
Maximum number of shares available for subscription (in shares)	19,165
Maximum total number of shares that may be subscribed (in shares)	28,750
OSA 2019-1 | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)						0
OSA 2019-1 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)						12
OSA 2019 LLY
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)					650,000
Total number of share options granted (in shares)					500,000
Total number of shares to which the share options were likely to give right (in shares)					500,000
Exercise price (in euros per share) | € / shares					€ 6.41
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	500,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	500,000
OSA 2019 LLY | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)					500,000
OSA 2019 LLY | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)					500,000
OSA 2019 LLY | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)					0
OSA 2020
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)				650,000
Total number of share options granted (in shares)				407,972
Total number of shares to which the share options were likely to give right (in shares)				407,972
Exercise price (in euros per share) | € / shares				€ 6.25
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	14,298
Total number of share options outstanding (in shares)	393,674
Maximum number of shares available for subscription (in shares)	172,147
Maximum total number of shares that may be subscribed (in shares)	393,674
OSA 2020 | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)				180,000
OSA 2020 | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)				120,000
OSA 2020 | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)				60,000
OSA 2020 | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)				104
OSA 2021-04 Ordinary
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)			850,000
Total number of share options granted (in shares)			143,200
Total number of shares to which the share options were likely to give right (in shares)			143,200
Exercise price (in euros per share) | € / shares			€ 13.74
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	143,200
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	143,200
OSA 2021-04 Ordinary | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			0
OSA 2021-04 Ordinary | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			13
OSA 2021-04 Performance
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)			1,000,000
Total number of share options granted (in shares)			428,000
Total number of shares to which the share options were likely to give right (in shares)			428,000
Exercise price (in euros per share) | € / shares			€ 13.74
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	428,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	428,000
OSA 2021-04 Performance | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			240,000
OSA 2021-04 Performance | Laurent LEVY
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			180,000
OSA 2021-04 Performance | Anne-Juliette HERMANT
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			60,000
OSA 2021-04 Performance | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)			14
OSA 2021-06 Performance
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)		1,000,000
Total number of share options granted (in shares)		60,000
Total number of shares to which the share options were likely to give right (in shares)		60,000
Exercise price (in euros per share) | € / shares		€ 12.99
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	60,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	60,000
OSA 2021-06 Performance | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)		60,000
OSA 2021-06 Performance | Bart VAN RHIJN
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options granted (in shares)		60,000
Total number of shares to which the share options were likely to give right (in shares)		60,000
OSA 2021-06 Performance | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)		0
OSA 2021-06 Ordinary
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options authorised (in shares)		850,000
Total number of share options granted (in shares)		60,000
Total number of shares to which the share options were likely to give right (in shares)		60,000
Exercise price (in euros per share) | € / shares		€ 12.99
Number of shares subscribed (in shares)	0
Total number of share options lapsed or cancelled (in shares)	0
Total number of share options outstanding (in shares)	60,000
Maximum number of shares available for subscription (in shares)	0
Maximum total number of shares that may be subscribed (in shares)	60,000
OSA 2021-06 Ordinary | Corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)		60,000
OSA 2021-06 Ordinary | Bart VAN RHIJN
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of share options granted (in shares)		60,000
Total number of shares to which the share options were likely to give right (in shares)		60,000
OSA 2021-06 Ordinary | Number of beneficiaries who are not corporate officers
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Total number of shares to which the share options were likely to give right (in shares)		0

Share-based payments - Addition

Share-based payments - Additional Information (Details) - € / shares	Sep. 16, 2014	Jun. 30, 2021
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Number of preceding trading days taken into account in the determination of the share price on the grant date		20 days
BSA 2014
Disclosure Of Detailed Information About Share-based Payments [Line Items]
Exercise price (in euros per share)	€ 17.67	€ 40

Share-based payments - Disclo_3

Share-based payments - Disclosure of Number of Founders' Warrants, Warrants and Free Shares Outstanding and Their Characteristics (Details) - EUR (€) € / shares in Units, € in Thousands

Apr. 20, 2021

Mar. 17, 2020

Mar. 11, 2020

Mar. 29, 2019

Jul. 27, 2018

Mar. 06, 2018

Jan. 07, 2017

Nov. 03, 2016

Feb. 02, 2016

Jun. 25, 2015

Jun. 10, 2015

Feb. 10, 2015

Sep. 16, 2014

Aug. 28, 2013

Apr. 10, 2013

Dec. 18, 2012

May 04, 2012

Jun. 30, 2021

Jun. 30, 2020

Disclosure of terms and conditions of share-based payment arrangement [line items]

Expense for the year

€ 1,398

€ 1,542

BSPCE

Disclosure of terms and conditions of share-based payment arrangement [line items]

Expense for the year

5

71

BSPCE 2012-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 5.26

Exercise price (in euro per share)

€ 5.26

Volatility

41.00%

Maturity (in years)

3 years 5 months 26 days

Risk-free rate

0.20%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 307

Expense for the year

0

0

BSPCE 2012-2

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 6.65

Exercise price (in euro per share)

€ 6.63

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 288

Expense for the year

0

0

BSPCE 2012-2 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

44.30%

Risk-free rate

0.84%

BSPCE 2012-2 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

47.60%

Risk-free rate

1.22%

BSPCE 2012-2 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years

BSPCE 2012-2 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

7 years 3 months 18 days

BSPCE 04-2013

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 6.30

Exercise price (in euro per share)

€ 6.30

Volatility

56.00%

Maturity (in years)

5 years

Risk-free rate

0.90%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 167

Expense for the year

0

0

BSPCE 08-2013

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 6.30

Exercise price (in euro per share)

€ 5.92

Volatility

256.00%

Maturity (in years)

7 years

Risk-free rate

0.90%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 152

Expense for the year

0

0

BSPCE 09-2014

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 18.68

Exercise price (in euro per share)

€ 18.68

Volatility

58.00%

Risk-free rate

0.64%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 932

Expense for the year

0

0

BSPCE 09-2014 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 6 months

BSPCE 09-2014 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years

BSPCE 09-2014 | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years 6 months

BSPCE 2015-2

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 18.57

Exercise price (in euro per share)

€ 18.57

Risk-free rate

0.39%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 650

Expense for the year

0

0

BSPCE 2015-2 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

BSPCE 2015-2 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

62.00%

BSPCE 2015-2 | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

61.00%

BSPCE 2015-2 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 6 months

BSPCE 2015-2 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years

BSPCE 2015-2 | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years 6 months

BSPCE 2015-3

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 20.28

Exercise price (in euro per share)

€ 20.28

Risk-free rate

0.56%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 483

Expense for the year

0

0

BSPCE 2015-3 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

61.00%

BSPCE 2015-3 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

62.00%

BSPCE 2015-3 | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

61.00%

BSPCE 2015-3 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 6 months

BSPCE 2015-3 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years

BSPCE 2015-3 | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years 6 months

BSPCE 2016 Ordinary

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 14.46

Exercise price (in euro per share)

€ 14.46

Risk-free rate

0.32%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 1,080

Expense for the year

0

0

BSPCE 2016 Ordinary | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

59.00%

BSPCE 2016 Ordinary | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

62.00%

BSPCE 2016 Ordinary | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

60.00%

BSPCE 2016 Ordinary | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 6 months

BSPCE 2016 Ordinary | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years

BSPCE 2016 Ordinary | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years 6 months

BSPCE 2016 Performance

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 14.46

Exercise price (in euro per share)

€ 14.46

Volatility

59.00%

Maturity (in years)

5 years

Risk-free rate

0.19%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 1,212

Expense for the year

5

63

BSPCE 2017 Ordinary

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.93

Exercise price (in euro per share)

€ 15.93

Risk-free rate

0.23%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 1,000

Expense for the year

0

8

BSPCE 2017 Ordinary | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

BSPCE 2017 Ordinary | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

61.00%

BSPCE 2017 Ordinary | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

59.00%

BSPCE 2017 Ordinary | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 6 months

BSPCE 2017 Ordinary | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years

BSPCE 2017 Ordinary | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

6 years 6 months

BSPCE 2017 Performance

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.93

Exercise price (in euro per share)

€ 15.93

Volatility

59.00%

Maturity (in years)

5 years

Risk-free rate

0.11%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 622

Expense for the year

0

0

BSPCE 2017

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.93

Exercise price (in euro per share)

€ 15.93

Volatility

59.00%

Maturity (in years)

5 years

Risk-free rate

0.11%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 627

Expense for the year

0

0

BSPCE 2017 Project

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.93

Exercise price (in euro per share)

€ 15.93

Volatility

59.00%

Maturity (in years)

5 years

Risk-free rate

0.11%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 94

Expense for the year

0

0

BSA

Disclosure of terms and conditions of share-based payment arrangement [line items]

Expense for the year

44

19

BSA 04-12

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 6

Exercise price (in euro per share)

€ 6

Volatility

49.00%

Maturity (in years)

10 years

Risk-free rate

0.96%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 183

Expense for the year

0

0

BSA 2013

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 6.30

Exercise price (in euro per share)

€ 6.37

Volatility

156.00%

Maturity (in years)

6 years

Risk-free rate

0.90%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 1

Expense for the year

0

0

BSA 2014

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 18.68

Exercise price (in euro per share)

€ 17.67

Volatility

57.00%

Maturity (in years)

5 years

Risk-free rate

0.41%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 0

Expense for the year

0

0

BSA 2015-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 17.67

Exercise price (in euro per share)

€ 17.67

Volatility

58.00%

Maturity (in years)

5 years

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 63

Expense for the year

0

0

BSA 2015-1 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.26%

BSA 2015-1 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.27%

BSA 2015-2 (a)

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 17.67

Exercise price (in euro per share)

€ 19.54

Risk-free rate

0.39%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 16

Expense for the year

0

0

BSA 2015-2 (a) | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

BSA 2015-2 (a) | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

BSA 2015-2 (a) | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

57.00%

BSA 2015-2 (a) | Tranche four

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

BSA 2015-2 (a) | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years

BSA 2015-2 (a) | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 1 month 6 days

BSA 2015-2 (a) | Tranche three

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 3 months 18 days

BSA 2015-2 (a) | Tranche four

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

5 years 4 months 24 days

BSA 2015-2 (b)

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 19.54

Exercise price (in euro per share)

€ 19.54

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 284

Expense for the year

0

0

BSA 2015-2 (b) | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

58.00%

Risk-free rate

0.25%

BSA 2015-2 (b) | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Volatility

60.00%

Risk-free rate

0.91%

BSA 2015-2 (b) | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

4 years 7 months 6 days

BSA 2015-2 (b) | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

9 years 7 months 6 days

BSA 2016o

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.74

Exercise price (in euro per share)

€ 13.74

Volatility

57.00%

Maturity (in years)

2 years 4 months 24 days

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 37

Expense for the year

0

0

BSA 2016p

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.74

Exercise price (in euro per share)

€ 13.74

Volatility

57.00%

Maturity (in years)

2 years 4 months 24 days

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 143

Expense for the year

0

0

BSA 2016-2

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.01

Exercise price (in euro per share)

€ 15.01

Volatility

57.00%

Maturity (in years)

2 years 4 months 24 days

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 0

Expense for the year

0

0

BSA 2017

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 15.76

Exercise price (in euro per share)

€ 15.76

Volatility

33.00%

Maturity (in years)

2 years 4 months 24 days

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 0

Expense for the year

0

0

BSA 2018

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.55

Exercise price (in euro per share)

€ 13.55

Volatility

38.00%

Maturity (in years)

4 years 9 months 18 days

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 2

Expense for the year

0

0

BSA 2018 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.70%

BSA 2018 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.10%

BSA 2018-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.55

Exercise price (in euro per share)

€ 13.55

Volatility

38.00%

Maturity (in years)

4 years 9 months 18 days

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 0

Expense for the year

0

0

BSA 2018-1 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.70%

BSA 2018-1 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.10%

BSA 2018-2

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 16.10

Exercise price (in euro per share)

€ 16.10

Volatility

38.00%

Maturity (in years)

4 years 9 months 18 days

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 1

Expense for the year

0

0

BSA 2018-2 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.70%

BSA 2018-2 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.10%

BSA 2019-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 11.66

Exercise price (in euro per share)

€ 11.66

Volatility

37.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 24

Expense for the year

0

0

BSA 2019-1 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.16%

BSA 2019-1 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.50%

BSA 2019-1 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

9 years 9 months 18 days

BSA 2019-1 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Maturity (in years)

9 years 10 months 24 days

BSA 2020

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.03

Exercise price (in euro per share)

€ 6.59

Volatility

38.00%

Maturity (in years)

10 years

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 19

Expense for the year

0

19

BSA 2020 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.13%)

BSA 2020 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.07%)

BSA 2021 (a)

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.47

Exercise price (in euro per share)

€ 13.47

Volatility

39.10%

Maturity (in years)

10 years

Risk-free rate

0.27%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 44

Expense for the year

44

0

BSA 2021 (b)

Disclosure of terms and conditions of share-based payment arrangement [line items]

Exercise price (in euro per share)

€ 13.64

Maturity (in years)

10 years

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 0

Expense for the year

0

0

AGA

Disclosure of terms and conditions of share-based payment arrangement [line items]

Expense for the year

983

1,246

AGA 2018-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 12.87

Exercise price (in euro per share)

€ 0

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 4,951

Expense for the year

16

224

AGA 2018-2

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 12.87

Exercise price (in euro per share)

€ 0

Risk-free rate

0.00%

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 75

Expense for the year

0

19

AGA 2019-1

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 10.90

Exercise price (in euro per share)

€ 0

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 4,776

Expense for the year

422

960

AGA 2019-1 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.19%

AGA 2019-1 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

0.141%

AGA 2020

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 5.90

Exercise price (in euro per share)

€ 0

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 287

Expense for the year

71

43

AGA 2020 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.74%)

AGA 2020 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.69%)

AGA 2021

Disclosure of terms and conditions of share-based payment arrangement [line items]

Share price (in euros)

€ 13.60

Exercise price (in euro per share)

€ 0

Yield

0.00%

Value of initial plan (in thousands of euros)

€ 4,869

Expense for the year

€ 473

€ 0

AGA 2021 | Tranche one

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.63%)

AGA 2021 | Tranche two

Disclosure of terms and conditions of share-based payment arrangement [line items]

Risk-free rate

(0.59%)

Share-based payments - Disclo_4

Share-based payments - Disclosure of Number of Shares Options Outstanding and Their Characteristics (Details) € / shares in Units, € in Thousands	Jun. 21, 2021EUR (€)uSDollarPerEuro€ / shares	Apr. 20, 2021EUR (€)uSDollarPerEuro€ / shares	Mar. 11, 2020EUR (€)uSDollarPerEuro€ / shares	Oct. 24, 2019EUR (€)uSDollarPerEuro€ / shares	Mar. 29, 2019EUR (€)uSDollarPerEuro€ / shares	Mar. 06, 2018EUR (€)uSDollarPerEuro€ / shares	Jan. 07, 2017EUR (€)uSDollarPerEuro€ / shares	Nov. 03, 2016EUR (€)uSDollarPerEuro€ / shares	Feb. 02, 2016EUR (€)uSDollarPerEuro€ / shares	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense for the year										€ 1,398	€ 1,542
OSA
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expense for the year										367	205
OSA 2016 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares									€ 13.05
Exercise price (in euros per share) | € / shares									€ 13.05
Risk-free rate									0.32%
Yield									0.00%
Value of initial plan (in thousands of euros)									€ 117
Expense for the year										0	0
OSA 2016 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									59.00%
OSA 2016 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									62.00%
OSA 2016 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility									60.00%
OSA 2016 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro									5.5
OSA 2016 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro									6
OSA 2016 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro									6.5
OSA 2016-1 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares									€ 13.05
Exercise price (in euros per share) | € / shares									€ 13.05
Volatility									59.00%
Maturity (in years) | uSDollarPerEuro									5,000
Risk-free rate									0.19%
Yield									0.00%
Value of initial plan (in thousands of euros)									€ 69
Expense for the year										0	0
OSA 2016-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares								€ 14.26
Exercise price (in euros per share) | € / shares								€ 14.26
Risk-free rate								0.04%
Yield								0.00%
Value of initial plan (in thousands of euros)								€ 27
Expense for the year										0	0
OSA 2016-2 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								58.00%
OSA 2016-2 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								62.00%
OSA 2016-2 | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility								59.00%
OSA 2016-2 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro								5.5
OSA 2016-2 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro								6
OSA 2016-2 | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro								6.5
OSA 2017 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares							€ 15.93
Exercise price (in euros per share) | € / shares							€ 14.97
Risk-free rate							0.23%
Yield							0.00%
Value of initial plan (in thousands of euros)							€ 31
Expense for the year										0	0
OSA 2017 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							58.00%
OSA 2017 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							61.00%
OSA 2017 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility							59.00%
OSA 2017 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro							5.5
OSA 2017 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro							6
OSA 2017 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro							6.5
OSA 2017 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares							€ 15.93
Exercise price (in euros per share) | € / shares							€ 14.97
Volatility							59.00%
Maturity (in years) | uSDollarPerEuro							5,000
Risk-free rate							0.11%
Yield							0.00%
Value of initial plan (in thousands of euros)							€ 35
Expense for the year										0	0
OSA 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares						€ 12.87
Exercise price (in euros per share) | € / shares						€ 12.87
Volatility						35.00%
Risk-free rate						0.00%
Yield						0.00%
Value of initial plan (in thousands of euros)						€ 252
Expense for the year										0	6
OSA 2018 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro						5.5
OSA 2018 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro						6
OSA 2018 | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro						6.5
OSA 2019-1
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares					€ 11.08
Exercise price (in euros per share) | € / shares					€ 11.08
Yield					0.00%
Value of initial plan (in thousands of euros)					€ 140
Expense for the year										13	27
OSA 2019-1 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility					38.10%
Risk-free rate					0.103%
OSA 2019-1 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility					37.40%
Risk-free rate					0.149%
OSA 2019-1 | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro					6
OSA 2019-1 | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro					6.5
OSA 2019-2
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares				€ 6.41
Exercise price (in euros per share) | € / shares				€ 6.41
Volatility				37.00%
Maturity (in years) | uSDollarPerEuro				10,000
Risk-free rate				0.40%
Yield				0.00%
Value of initial plan (in thousands of euros)				€ 252
Expense for the year										0	0
OSA 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares			€ 6.25
Exercise price (in euros per share) | € / shares			€ 6.25
Volatility			38.00%
Maturity (in years) | uSDollarPerEuro			10,000
Risk-free rate			0.31%
Yield			0.00%
Value of initial plan (in thousands of euros)			€ 939
Expense for the year										225	172
OSA 2021-04 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares		€ 13.60
Exercise price (in euros per share) | € / shares		€ 13.74
Yield		0.00%
Value of initial plan (in thousands of euros)		€ 684
Expense for the year										80	0
OSA 2021-04 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		38.90%
Risk-free rate		(0.38%)
OSA 2021-04 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		37.80%
Risk-free rate		(0.33%)
OSA 2021-04 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility		38.30%
Risk-free rate		(0.28%)
OSA 2021-04 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro		5.5
OSA 2021-04 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro		6
OSA 2021-04 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro		6.5
OSA 2021-04 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares		€ 13.60
Exercise price (in euros per share) | € / shares		€ 13.74
Volatility		39.10%
Maturity (in years) | uSDollarPerEuro		10,000
Risk-free rate		0.03%
Yield		0.00%
Value of initial plan (in thousands of euros)		€ 1,816
Expense for the year										39	0
OSA 2021-06 Ordinary
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares	€ 12.20
Exercise price (in euros per share) | € / shares	€ 12.99
Yield	0.00%
Value of initial plan (in thousands of euros)	€ 246
Expense for the year										4	0
OSA 2021-06 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	39.20%
Risk-free rate	(0.35%)
OSA 2021-06 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	37.80%
Risk-free rate	(0.30%)
OSA 2021-06 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Volatility	38.10%
Risk-free rate	(0.26%)
OSA 2021-06 Ordinary | Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro	5.5
OSA 2021-06 Ordinary | Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro	6
OSA 2021-06 Ordinary | Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity (in years) | uSDollarPerEuro	6.5
OSA 2021-06 Performance
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share price (in euros) | € / shares	€ 12.20
Exercise price (in euros per share) | € / shares	€ 12.99
Volatility	39.10%
Maturity (in years) | uSDollarPerEuro	10,000
Risk-free rate	0.13%
Yield	0.00%
Value of initial plan (in thousands of euros)	€ 212
Expense for the year										€ 5	€ 0

Net financial income (loss) - S

Net financial income (loss) - Summary of Net Financial Income (Loss) (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Net Financial Income (Loss) [Abstract]
Income from cash and cash equivalents	€ 0	€ 0
Foreign exchange gains	2,511	177
Other financial income	0	56
Total financial income	2,511	234
Interest cost	(2,960)	(2,219)
IFRS 16 related interests	(152)	(169)
Foreign exchange losses	(39)	(39)
Total financial expenses	(3,152)	(2,428)
Financial income (loss)	€ (640)	€ (2,194)

Net financial income (loss) - A

Net financial income (loss) - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure of financial instruments by type of interest rate [line items]
Foreign exchange gains	€ 2,511	€ 177
Interest costs	2,960	€ 2,219
EIB loan
Disclosure of financial instruments by type of interest rate [line items]
Interest costs	2,900
EIB loan | Variable interest rate
Disclosure of financial instruments by type of interest rate [line items]
Accumulated variable interest expense accrual	2,000
EIB loan | Fixed interest rate
Disclosure of financial instruments by type of interest rate [line items]
Interest expense on borrowings	889
HSBC bank account denominated In US dollars
Disclosure of financial instruments by type of interest rate [line items]
Foreign exchange gains	€ 2,400

Loss per share - Schedule of Ba

Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Earnings Per Share [Abstract]
Net loss for the period (in thousands of euros)	€ (30,420)	€ (20,579)
Weighted average number of shares (in shares)	34,619,072,000	22,608,408,000
Basic loss per share (in euro per share)	€ (0.88)	€ (0.91)
Diluted loss per share (in euro per share)	€ (0.88)	€ (0.91)

Loss per share - Additional Inf

Loss per share - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021shares
Disclosure Of Earnings Per Share [Abstract]
Potential additional ordinary shares that are considered antidilutive (in shares)	643,818

Commitments (Details)

Commitments (Details) € in Thousands, $ in Millions	1 Months Ended		4 Months Ended	6 Months Ended		30 Months Ended
	Mar. 31, 2021USD ($)	Jul. 31, 2018	Jun. 30, 2021USD ($)	Jun. 30, 2021USD ($)patientlease_contract	Jun. 30, 2021EUR (€)patientlease_contract	Jun. 30, 2021USD ($)	Jan. 31, 2019USD ($)
Disclosure of contingent liabilities [line items]
Guarantee of EIB loan by subsidiaries, minimum threshold		5.00%
Number of short term leases | lease_contract				1	1
Annual short term lease expense | €					€ 140
Annual lease expense | €					€ 10
Royalties agreement, period				6 years	6 years
MD Anderson Cancer Center, NBTXR3
Disclosure of contingent liabilities [line items]
Number of patients in clinical trial | patient				340	340
Contractual commitments, payment							$ 11
Contractual commitments, milestone payment						$ 2
MD Anderson Cancer Center, NBTXR3 | Bottom of range
Disclosure of contingent liabilities [line items]
Milestone payment increase				$ 2.2
MD Anderson Cancer Center, NBTXR3 | Top of range
Disclosure of contingent liabilities [line items]
Milestone payment increase				16.4
Termination of PharmaEngine collaboration agreement, NBTXR3
Disclosure of contingent liabilities [line items]
Contractual commitments, payment	$ 2.5		$ 4	$ 6.5	€ 5,400
Contractual commitments, milestone payment upon receipt of clinical study reports	1
Contractual commitments, milestone payment upon second regulatory approval	$ 5
Royalties agreement, period	10 years
EIB loan
Disclosure of contingent liabilities [line items]
Royalties agreement, period		6 years
Minimum | EIB loan
Disclosure of contingent liabilities [line items]
Estimated financial effect of contingent liabilities | €					€ 35,000

Related parties - Summary of Ke

Related parties - Summary of Key Management Personnel Compensation (Details) - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Related Party [Abstract]
Salaries, wages and benefits	€ 610	€ 687
Share-based payments	743	859
Supervisory Board’s fees	245	35
Total compensation to related parties	€ 1,598	€ 1,581

Subsequent events (Details)

Subsequent events (Details) € in Thousands	1 Months Ended				6 Months Ended		12 Months Ended
	Jul. 31, 2020	Mar. 31, 2019EUR (€)	Oct. 31, 2018EUR (€)	Jul. 31, 2018EUR (€)tranche	Jun. 30, 2021EUR (€)	Jun. 30, 2020EUR (€)	Dec. 31, 2018EUR (€)tranche
Disclosure of non-adjusting events after reporting period [line items]
Increase in loans and conditional advances					€ 0	€ 5,350
EIB loan
Disclosure of non-adjusting events after reporting period [line items]
Number of tranches | tranche				3			3
Increase in loans and conditional advances		€ 14,000	€ 16,000
Borrowing, deferment period to request funds	12 months
EIB loan | Top of range
Disclosure of non-adjusting events after reporting period [line items]
Notional amount				€ 40,000			€ 40,000